**Table of Contents**

Introduction .............................................................................................................................. 1

A Sampling of Creighton University’s Research Endeavors................................................. 2

<table>
<thead>
<tr>
<th>Department</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Center for Health Policy and Ethics</td>
<td>2</td>
</tr>
<tr>
<td>College of Arts and Sciences</td>
<td>3</td>
</tr>
<tr>
<td>Department of Exercise Science</td>
<td>3</td>
</tr>
<tr>
<td>Department of History</td>
<td>3</td>
</tr>
<tr>
<td>Department of Physics</td>
<td>6</td>
</tr>
<tr>
<td>Department of Political Science &amp; International Relations</td>
<td>6</td>
</tr>
<tr>
<td>College of Business</td>
<td>7</td>
</tr>
<tr>
<td>School of Dentistry</td>
<td>7</td>
</tr>
<tr>
<td>School of Law</td>
<td>8</td>
</tr>
<tr>
<td>School of Medicine</td>
<td>10</td>
</tr>
<tr>
<td>Department of Anesthesiology</td>
<td>10</td>
</tr>
<tr>
<td>Department of Preventive Medicine</td>
<td>10</td>
</tr>
<tr>
<td>Department of Medicine: Division of Allergy/Immunology</td>
<td>11</td>
</tr>
<tr>
<td>Department of Medicine: Division of Cardiology</td>
<td>12</td>
</tr>
<tr>
<td>Department of Medicine: Division of Dermatology</td>
<td>15</td>
</tr>
<tr>
<td>School of Nursing</td>
<td>15</td>
</tr>
<tr>
<td>School of Pharmacy and Health Professions</td>
<td>16</td>
</tr>
<tr>
<td>Office of Research</td>
<td>16</td>
</tr>
<tr>
<td>Office of Interprofessional Scholarship, Service and Education</td>
<td>18</td>
</tr>
<tr>
<td>Department of Occupational Therapy</td>
<td>19</td>
</tr>
<tr>
<td>Department of Physical Therapy</td>
<td>19</td>
</tr>
<tr>
<td>Department of Pharmacy Practice</td>
<td>20</td>
</tr>
<tr>
<td>Department of Pharmacy Sciences</td>
<td>21</td>
</tr>
</tbody>
</table>

Publications ............................................................................................................................ 22

| College of Arts and Sciences | 22 |
| College of Business | 31 |
| School of Dentistry | 32 |
| School of Law | 33 |
| School of Medicine | 33 |
| School of Nursing | 56 |
| School of Pharmacy and Health Professions | 58 |
| Other University Publications | 63 |
| Vice President for Health Sciences | 63 |

Grants ..................................................................................................................................... 64

| College of Arts and Sciences | 64 |
| School of Dentistry | 65 |
| School of Law | 67 |
| School of Medicine | 67 |
| School of Nursing | 89 |
| School of Pharmacy and Health Professions | 90 |
| Other Creighton Grants | 92 |
| Vice President for Academic Affairs | 92 |
| Vice President for Health Sciences | 93 |

Creative and Artistic Works .................................................................................................... 94
Introduction

Usually we speak of professors in the plural, but what is at stake is more than the sum of so many individual commitments and efforts. It is a sustained interdisciplinary dialogue of research and reflection, a continuous pooling of expertise. The purpose is to assimilate experiences and insights according to their different disciplines in "a vision of knowledge which, well aware of its limitations, is not satisfied with fragments but tries to integrate them into a true and wise synthesis" about the real world.


Former Superior General of the Society of Jesus, Peter Hans-Kolvenbach, challenges Jesuit higher education to engage in sustained interdisciplinary dialogue of research and reflection to extend our intellectual resources towards solving real world problems. We believe that Creighton University as a complex institution with strong liberal arts and science along with several professional schools in a relatively small university community provides the perfect environment for rich interdisciplinary work. The scholarly work done by faculty at Creighton represents the evidence of this kind of meaningful collaboration across our campus. This is the twentieth Faculty Bibliography produced annually by Creighton University's Graduate School under the guidance of the University Research Council (URC). The bibliography now documents the scholarly accomplishments of the University community for the calendar year 2011 instead of tracking documents across the academic year. The bibliography includes reports from various units on campus (departments, centers, or offices) that highlight the broad range of research and scholarly activity across the campus. These reports are followed by a listing of the scholarly accomplishments of Creighton faculty, including peer-reviewed articles, book chapters, and books; funded grants; and student dissertations, theses and a new addition this year, creative works. The bibliography does not include papers in press or abstracts of professional presentations at local, regional, national or international meetings.

The contributions in this bibliography demonstrate the rich diversity and broad application of scholarship across the Creighton campus from the traditional scholarship of discovery to scholarly work of application, integration, engagement, teaching and learning and creative work. There is strong evidence that Creighton faculty are committed teacher-scholars and true stewards of their disciplines. As stewards, Creighton faculty has a sense of purpose beyond themselves, focusing on who students become and what they will do in building a better world with “the least and with all.”

Special thanks go to Richard Jizba and his staff at the Health Sciences Library, LuAnn Schwery, Assistant Dean, Graduate School, and Pat Kindelan who helped to gather and compile the information that makes up this Bibliography.

Thomas Murray, Ph.D.
Associate VP for Research, Health Sciences
Chair, Department of Pharmacology
School of Medicine

Gail M. Jensen, Ph.D.
Dean, Graduate School and University College
Associate VP for Research, Academic Affairs

Faculty Bibliography   Page 1   2011
A Sampling of Creighton University's Research Endeavors

Center for Health Policy and Ethics

Established in 1984, the Center for Health Policy and Ethics is a multidisciplinary group of scholars dedicated to the study and teaching of ethical dimensions of health care and health policy. Scholarship at the Center for Health Policy and Ethics responds to the challenge of ethical issues raised by a complex and fractured health care system, inequities in health and health care delivery, increasingly ill patients, and public health problems. The multidisciplinary nature of the Center for Health Policy and Ethics encourages a variety of perspectives informed by disciplinary insights. Thus, the topics of scholarly inquiry, conceptual analysis, moral discernment, and discussion cover a wide range of issues under the overarching umbrella of health policy and ethics. One example of a long-standing Center effort to encourage the development of ideas and questions into scholarly projects and publications is the Roundtable Series that is held once a month or more often at the Center. During an hour long session, ethical topics are presented ranging from the earliest stages of development to finished products but always allowing for input from a diverse audience.

The research and scholarly endeavors of Center for Health Policy and Ethics faculty are deeply influenced by and contribute to Creighton University's quest for academic excellence, social justice, and better ways to partner with students, faculty, staff and members of the community to realize the richness of diverse gifts and contributions to fuller understanding. The following notable examples of scholarly work reflect sustained interest in clinical ethical issues, professional education and development, health and health care issues, and broader social justice issues.


Issues of health policy and ethics will continue to demand scholarly inquiry and public attention. Critical concerns about ethics education and the continuing growth of two graduate degree programs, the Master of Science in Health Care Ethics and Master of Public Health, in the Center will require closer examination of student learning and outcomes especially those obtained in an online environment. The health care system will continue to develop, policies will change, and regulations in research in health care and public health will introduce challenges that inevitably lead to new moral considerations. Faculty at the Center will continue to make important contributions in these areas and direct attention to issues and concerns that align with the Center's mission as they have done for more than a quarter of a century.
College of Arts and Sciences

Department of Exercise Science

In the Department of Exercise Science, Dr. G. Patrick Lambert conducts research on gastrointestinal (GI) physiology and body fluid balance as it relates to exercise in humans. Specifically, he studies GI barrier dysfunction, gastric emptying, and intestinal absorption. Dr. Lambert received a grant in 2011 totaling $16,768 from the Zinpro Corporation to conduct biochemical analysis of equine samples to determine GI barrier dysfunction. In 2011, he also published one research article in the *Journal of Exercise Physiology online*, one proceedings paper in *The Measure of Performance: Proceedings of the 2011 Equine Conference*, and one book chapter in *ACSM's Advanced Exercise Physiology*. In addition, one of his undergraduate students presented research results at the 2011 American College of Sports Medicine Annual meeting in Denver. Dr. Lambert's interest in GI physiology has resulted in collaboration with Dr. Stephen Lanspa at the Creighton University School of Medicine.

Department of History

*Research Overview*

Faculty members in the Department of History participate in a robust research and publishing program. Five of our scholars have published monographs with prestigious university presses since 2010. The books have examined such diverse areas as: the origins of Islamic radicalism; the social impact of national security decisions on the home front during WWII; sexual knowledge and social reform in Vienna; Spanish nationalism in the Atlantic world; and Jesuit missionization and indigenous Christianities in colonial North America. Department members have also published a number of journal articles and book chapters. The two books published in 2011 were:


Department of Physics

*Research Overview*

In 2011, faculty members in the Physics Department conducted research in the general areas of biophysics, low-energy atomic-collision physics and x-ray fluorescence, relativistic heavy ion physics, particle physics, laser physics, condensed matter physics, astrophysics, and cosmology. Much of this research is supported by federal and/or local funding. The department encourages collaborative research interaction with Creighton faculty in the Departments of Biology, Chemistry, Biomedical Sciences and the Energy Technology Program, as well as external collaborations. Specific research interests are:

- Characterization and detection of dark matter; prompt atmospheric lepton flux in high energy cosmic rays; high-energy cosmic rays beyond the GZK cutoff.
- Implementation of high performance computing techniques to address protein conformational dynamics and pathological protein folding.
- Observation and analysis of active galactic nuclei using UV, optical, IR, and X-ray spectra from space-based and large ground-based observatories; Photoionization modeling of astrophysical plasmas, Studies of energetic mass outflows from quasars.
- Atomic inner-shell ionization. X-ray fluorescence.
- Development and application of novel optical techniques to biology and medicine; Multiphoton and confocal laser scanning fluorescence microscopy; Molecular photophysics. Vis/Near-IR tissue spectroscopy; Photodynamic therapy (PDT) of Cancer. Studies of cellular mechanics use an optical stretcher apparatus and holographic microscope.
- Ionic motion in glasses; dynamic light scattering of the glass transition.
Nanoscale systems involving novel magnetic and electronic phenomena at heterostructure interfaces; Solar Cells; self-assembly of block copolymers.

High-energy nuclear physics (relativistic heavy ion physics) in STAR collaboration at RHIC (Brookhaven National Laboratory) and ALICE collaboration at the LHC (CERN).

**Specific Areas of Research**

**Astroparticle Physics**

Astroparticle physics is an interdisciplinary and quickly expanding field which applies theoretical particle physics solutions to astrophysical problems. Examples of research in astroparticle physics include dark matter, dark energy, cosmic ray fluxes, neutrino masses, and large scale structure of the universe (and many more). Dr. Duda’s interests involve characterization and detection of dark matter, the study of the prompt atmospheric lepton flux in high energy cosmic rays and the origin of high-energy cosmic rays beyond the GZK cutoff.

_Faculty: Gintaras Duda, Ph.D._

**Observational Astrophysics**

Astrophysics involves the study of the physical processes, interactions, and properties of the celestial objects that comprise the universe. The Creighton Observational Astrophysics Research Group is involved in projects that explore the fundamental nature of active galactic nuclei (AGN), which are highly energetic centers of galaxies powered by matter falling into supermassive black holes, and the effect of AGN on their cosmic environments. Much of the current focus is on high energy mass outflows from AGN using spectra from space-based and large ground-based telescopes observing at X-ray, UV, optical, and infrared wavelengths. These multiwavelength studies seek to determine the basic properties of AGN outflows, such as the driving mechanism, source of material, and contribution to the overall energetic of AGNs. They also have implications for understanding the mechanisms underlying AGN evolution, the growth of black holes in galactic nuclei, and the potential impact that AGNs have on galaxy formation.

_Faculty: Jack Gabel, Ph.D._

**Atomic Physics**

The main research effort is atomic inner-shell ionization physics involving measurement of characteristic x-rays from atoms excited by either the Coulomb interaction with an accelerated charged particle or by photo-absorption of discrete-energy x-rays. Basic physics studies have been done on a wide range of elements to determine the probabilities (cross sections) of ejecting inner-most electrons from atoms. Further details of the interaction process between the atomic electrons and the incident charged particles or photons, such as multiple ionization, can be found from analyzing intensity ratios of emitted x-rays. One application studied at Creighton involves determining the absolute concentration of trace elements in human whole blood and blood plasma by means of analyzing characteristic x-rays excited from trace elements in freeze-dried blood samples that were bombarded by protons produced in our accelerator. Other applications have been in the area of space physics in which the laboratory techniques of x-ray fluorescence were used to assist NASA in the determination of the surface composition of the near-earth asteroid Eros by analyzing the characteristic x-rays emitted from the surface when struck by x-rays from the sun.

_Faculty: Sam Cipolla, Ph.D._

**Biophysical Optics**

Progress in biophysics is intrinsically connected with the development of novel technologies and experimental methodologies to characterize the nature of living organisms. In the past, optical techniques have played a key role in expanding our vision into the biological realm, and the frontier is equally promising.
Current research areas include:

- Metabolic Imaging using multiphoton excited NADH and Flavoprotein fluorescence intensity and lifetime
- Digital Holographic Microscopy for the measurement of shape index of refraction of living cells
- Bone cell Biomechanics measurements using a dual-beam optical stretcher
- Optimization of Novel Lipophilic Tracer dyes developed by MTTI and in collaboration with University of Iowa.

**Faculty:** Michael Nichols, Ph.D

**Computational Molecular Biophysics**

The long term research goal of the group is to establish a theoretical model with the power to predict the response of protein conformational dynamics to surfaces. The nature of these interactions makes high performance multi-scale computer modeling a unique tool to probe the complexity of the energy landscape at an atomic level unreachable by experimental techniques. Current projects examine proteins and peptides hallmark of neurodegenerative diseases, such as Alzheimer's and prion diseases, to provide insight into the pathobiological function they play when interacting with the plasma membrane.

**Faculty:** Patricia Soto, Ph.D.

**Condensed Matter Physics**

Condensed matter physics is a broad field of inquiry encompassing size scales from the atomic to human and energy scales from 0.1 eV to several eV. The field emerged in the 1970s as an extension of successful solid state (crystalline) physics to include various types of soft matter including liquids, liquid crystals, self-assembled membranes, polymers and cooperative processes including phase transitions and critical phenomena.

The majority of the research in the Creighton Condensed Matter Group involves exploration of dynamics in complex materials using a variety of spectroscopy techniques. Current research areas include:

- Cryopreservation - investigation of the role of simple sugar solutions in the cryopreservation of biological proteins and tissues using both photon correlation spectroscopy and fluorescence correlation spectroscopy.
- Supercooled Liquids - investigation of the dynamics of ultraslow liquids near their glass transition point using photon correlation spectroscopy.
- Ion Conduction in Amorphous Solids - investigation of ion dynamics in glass materials using impedance spectroscopy.

**Faculty:** David Sidebottom, Ph.D.

**High Energy Nuclear Physics**

Students and faculty at Creighton University are involved in several cutting edge projects in nuclear physics.

At the Relativistic Heavy Ion Collider (RHIC) at Brookhaven National Laboratory in Long Island, New York, researchers are colliding gold nuclei together at nearly the speed of light in order to create a phase of matter known as the quark-gluon plasma which has not existed since the time of the Big Bang. Creighton is working with the Solenoidal Tracker at RHIC (STAR), primarily focusing on the detector control systems and peripheral collisions.

Creighton also is part of a large collaboration based at the European Organization for Nuclear Research (CERN) in Geneva, Switzerland. There, the new Large Hadron Collider (LHC) reaches unprecedented energies in particle physics with the hope of making new discoveries and advancing our understanding of fundamental particles and interactions. Creighton is involved in A Large Ion Collider Experiment (ALICE), one of the three main experiments at the LHC, specifically designed to further study the quark-gluon plasma and the primordial universe.

**Faculty:** Michael Cherney, Ph.D.; Thomas McShane, S.J.; Janet Seger, Ph.D.
Department of Political Science and International Relations

Dr. Terry Clark's current research focus is on the fuzzy math spatial modeling project. The project's long-term goals are 1) to improve the capacity of spatial models to predict stable outcomes, 2) to improve the empirical validity of those predictions, and 3) to provide a touchstone for further applications of fuzzy mathematics in the social sciences.

Dr. Susan Crawford's research interests include public management topics such as the roles of religious institutions in public policy, tools for analyzing the impact of rules and norms on behavior, and the roles of government and other community institutions in facilitating health information access in rural communities. Dr. Crawford’s current research focuses on rural community infrastructure and health information. This research is funded by a federal Agency for Healthcare Research and Quality grant (Principal investigator: Kimberly Galt). Nine Health Administration and Policy students and one political science student and one EMS student have been engaged in this research. Most have had the opportunity to present posters and/or papers on this research.

Dr. Scott Hendrickson’s teaching and research focuses on American politics, with a particular emphasis on law and courts. He is particularly interested in the ways in which institutions structure and constrain the behavior of judges and other legal actors. His current research utilizes both the formal and informal rules by which the Supreme Court selects its case docket to examine the effect of these rules on judicial behavior.

Dr. Maorong Jiang’s research on China and Taiwan argues that Western notions of sovereignty mask a reality where cultural affinity can be the basis of a “One China” reconciliation in the future. His current work applies this perspective to the tensions between China and Tibet, and North and South Korea.

Dr. Phil Meeks’ current research looks at the impact of globalization on French foreign policy, with particular emphasis on the roles played by farmers, international migrants, and multi-national corporations.

Dr. Erika Moreno examines variations in democratic institutional design in the developing world, with an emphasis on institutions of accountability (e.g. the judiciary, ombudsman, etc.) and inter-branch relations (executive-legislative relations). I have also conducted examinations of party systems and their impact on inter-branch relations, representation, and policy creation in the developing world, especially across Latin America.

Dr. Graham Ramsden’s current research focus is Canadian politics - specifically the composition of the Canadian Senate, and who the Prime Minister appoints to that chamber and why.

Dr. Rick Witmer is a specialist in Native American politics. He is particularly interested in explaining how Native Americans try to influence policy at the level of state and local government. His research also examines how Native Americans attempt to influence campaign and elections.

Dr. James Wunsch’s current research concentrates on problems facing democracy and governance in Africa. His work focuses on the impact of rents, both domestic and international, on national governments, and how their persistence has undercut the performance and accountability of African governments to Africa’s peoples. This has destroyed the authority and effectiveness of national level institutions. Dr Wunsch has focused on sub-national institutions as alternate non-rent based governance arrangements, and what affects their potential to provide improved governance and genuine democracy."
College of Business

The College of Business consists of the departments of Economics and Finance, Marketing and Management, Accounting, and Business Intelligence and Analytics. While faculty from all departments published research in the 2011 year, the management group led the way in volume of publications for the year.

With specialties ranging from biotechnology to business law, the diverse interests of the management faculty produced a globe-spanning array of research. For example, Mr. George McNary and co-authors focused on Omaha-area collective bargaining issues for their publication in the *Journal of Legal, Ethical and Regulatory Issues*. Dr. Anne York and her co-author reported on biotechnology industry development in Asia.

In addition to the diverse geographic focus, College of Business faculty published on a wide range of topics. For example, business intelligence and analytics professors Leida Chen and Ravi Nath researched and wrote about the kinds of hurdles that impede mobile work. Dr. Peter Gallo and MBA alumna Laura Christensen investigated the relationships among sustainability practices, firm ownership and firm size. Economics faculty members Dr. Charlie Braymen and Dr. Kristie Briggs (and co-author) studied decisions related to research, development and exportation in firms that are relatively new.

In general, the publication portfolio of faculty members from the College of Business represents research on a wide range of business-related topics and issues. It is domestic as well as international in focus. College of Business faculty published with Creighton colleagues as well as former graduate students, professional colleagues, and faculty members at other institutions. This research is consistent with college objectives as well as university mission in that it spans a range of business topics, includes recent graduate students, is global, and addresses social and ethical issues.

School of Dentistry

Research in the School of Dentistry has expanded substantially over the last decade with growing extra-mural funding support from the National Institutes of Health (NIH), the Agency for Health Care Research and Quality (AHRQ) and numerous foundations and multinational corporations. The School has active programs in basic molecular biological science, dental materials science, health services research, translational and clinical trials, and behavioral intervention research. The Master of Science in Oral Biology program has rapidly achieved success since being launched two years ago as an interdisciplinary research thesis program within the School or Dentistry and in collaboration with the College of Arts and Sciences.

Active areas of research include:

- Basic molecular studies evaluating the role of small ribonucleic acid (miRNA) and cell cycle control molecules in cell differentiation, proliferation and function. These investigations are targeted primarily at systems in the cranio-facial complex, with an emphasis on discoveries related to hearing and balance.

- Studies evaluating lysophosphatidic acid (LPA) and cytokine regulation of G proteins especially in wound healing. These investigations are learning about these processes and their relationship to inflammation, periodontal disease and oral wound healing.

- Health services research evaluating the effectiveness and impact of care provision programs improving oral health care access for children and underserved rural communities.

- Basic research into self-healing dental materials that are engineered for longevity and strength in the oral environment.
Microencapsulation methods that will lead to materials with a controlled release of bioavailable remineralizing agents. These investigations could lead to dental restorative with caries prevention properties.

Translational and clinical research of new dental materials including investigations in dental adhesives and composite resins, dental cements, fatigue life of new materials and the clinical effectiveness of new dental therapies and devices.

Research and educational initiatives in Oral Cancer prevention and diagnosis.

School of Law

The diversity of faculty research interests and scholarly pursuits, including a listing of publications and other endeavors, is summarized in the individual faculty research bibliographies that appear below. References are made to their most recent publishing ventures. For historical bibliographies and citation to prior works, please visit the faculty page on the Law School's website. Below are brief summaries of research interests.

Terry Anderson is an expert in criminal law, contracts, and secured transactions. He received his J.D. from the University of North Dakota where was a member of the Order of the Coif and an editor of the North Dakota Law Review.

Kay Andrus, currently the director of the Law School’s Klutznick Law Library, is an expert in legal research and a recognized authority on Nebraska legal research. He received his J.D. from Brigham Young University School of Law.

Bruce Aronson is an expert in corporate governance in addition to being an authority on Japanese business law. Prof. Aronson is fluent in Japanese and is currently on leave for a Fulbright in Tokyo. He received his J.D. from Harvard University School of Law.

Patrick Borchers is an internationally recognized expert in the area of conflicts of law. The current focus of his research concerns private international law. He is also an authority on civil procedure and the law of transnational expropriation of property. He also serves as Vice President of the University for Academic Affairs. Prof. Borchers received his J.D. from the University of California at Davis School of Law.

Eric Chiappinelli is an authority on corporations and business law. He served as Dean of the Law School from 2008 to 2009. Prof. Chiappinelli received his J.D. from Columbia University School of Law.

Marianne Culhane, currently the dean of the Law School, focuses primarily on empirical research in consumer bankruptcy law. With Michaela White, she served as a consultant to the Rand Corporation on two empirical studies of the 2005 amendments to the Bankruptcy Code. She received her J.D. from the University of Iowa College of Law.

Craig Dallon, currently the Associate Dean for Academic Affairs of the Law School, conducts research in the areas of copyright and trademark law as well as being an expert on torts and professional responsibility (legal ethics). He received his J.D. from Brigham Young University School of Law where he served as an editor of the BYU Law Review.

Michael Fenner’s primary research interests are evidence law, Nebraska civil trial law (particularly Nebraska pattern jury instructions for use in civil cases), and American constitutional law. He holds the Koley ’54 Professorship in Constitutional Law. Prof. Fenner received his J.D. from the University of Missouri at Kansas City School of Law.
Michael Kelly researches in the areas of international use of force theory. He is also an expert on Native American law and comparative constitutional law – often working with foreign groups on constitutional drafting for their respective states and regions. Prof. Kelly received his J.D. from Indiana University School of Law where was an editor of the Indiana International & Comparative Law Review.

Raneta Lawson Mack is an expert in both foreign and domestic criminal law and procedure. Her current research is in the area of cyber-crime and the international aspects of that conduct, for which she will develop a report on behalf of the United States to be presented at an international congress of international criminal law experts. She received her J.D. from the University of Toledo School of Law.

Collin Mangrum hold the Yossem Chair in Legal Ethics and researches in the areas of scientific evidence, trial practice and the role of religion in society and the division between church and state. He has travelled to Jerusalem, Israel on field research in furtherance of his religion in society studies. Prof. Mangrum received his J.D. from the University of Utah School of Law.

Ken Melilli’s research focuses on evidence law and trial practice. He is also an expert in criminal law and procedure. Prof. Melilli received his J.D. from New York University School of Law.

Nicholas Mirkay is an expert on the taxation of non-profit entities as well as federal income taxation, state and local taxation, trusts and estates and business associations. He received his J.D. from the University of Missouri at Columbia School of Law where he was an editor of the Missouri Law Review.

Edward Morse focuses his research on taxation, economic development, and law and technology. He holds the McGrath-North Chair in Business Law. Prof. Morse’s current publications focus on legal problems of data mining. He received his J.D. from the University of Michigan School of Law.

Eric Pearson, currently the associate dean for administration and finance at the Law School, continues to focus his research on the relationship of the constitutional law of takings to substantive due process and the National Environmental Policy Act as well as the public trust doctrine. He received his J.D. from Duquesne University School of Law where served on the Duquesne Law Review and was a member of the Order of Barristers.

Stephen Sieberson is an expert on the international law of human rights, the constitutional law of the European Union and international trade regulation. Prof. Sieberson is on faculty exchange to Spain in 2013. He received his J.D. from the University of Iowa College of Law where he was the founding editor of the Journal of Corporation Law.

Palma Strand conducts research on the interdisciplinary theory of the kind of civic relationships and networks that underlie and support a civic concept of law and that are consistent with voice and resonance. She also researches substantive and structural issues related to democracy and the ways in which current jurisprudence fails to adequately account for them. Prof. Strand received her J.D. from Stanford University School of Law.

Larry Teply is an expert in the areas of negotiation, dispute resolution, arbitration, civil procedure and client counseling. His books in these fields have been widely adopted at law schools across the country. He received his J.D. from the University of Florida School of Law where he was a member of the Order of the Coif and an editor of the Florida Law Review.

Ronald Volkmer holds the Kellegher Professorship in Trusts & Estates. He is an expert in the areas of property law, mediation, estate planning and trusts and estates. Prof. Volkmer received his J.D. from the Creighton University School of Law where he was the founding editor of the Creighton Law Review.

Sean Watts’ primary research interests focus on the regulation of armed conflict, and he is an expert in the laws of war, public international law, international criminal law and constitutional law. Prof. Watts
received his J.D. from the College of William & Mary School of Law where he was an editor of the William & Mary Law Review.

David Weber’s research interests are in the areas of commercial law and immigration law. He was nominated for the Young Scholars Medal of the American Law Institute for his work in law reform in these areas. Prof. Weber received his J.D. from the University of Minnesota School of Law where he was a member of the Order of the Coif and the editor in chief of the Minnesota Journal of Global Trade.

Michaela White is an expert in the field of bankruptcy law as well as contracts, sales, corporate reorganization and debtor-creditor relations. She received her J.D. from Creighton University School of Law where she was an editor of the Creighton Law Review.

Ralph Whitten is an authority on the conflicts of law, federal courts, and civil procedure. He currently holds the Sekt Chair in Law. Prof. Whitten received his J.D. from the University of Texas School of Law where he was a member of the Order of the Coif.

School of Medicine

Department of Anesthesiology

Research in the Department of Anesthesiology is designed and performed to acquire knowledge that leads to improved care for their patients and better lives for all patients. The research and scholarly endeavors of the Department of Anesthesiology encourage and promote physician collaboration both within the department and with other departments. Most often the collaboration has been with physicians in the Surgery and Obstetrics / Gynecology departments. The goal of these endeavors is to use knowledge gained to improve medical care for all patients. The Clinical research has been mostly in the areas of pain control following Cesarean Section, treatment for post-operative Ileus and prevention and treatment of post-operative Nausea and vomiting.

2011 Areas of Research — Faculty: Edward McGonigal MD., Co-Investigator
Continuous Local Anesthesia (OnQ Pump) versus Intrathecal morphine for post-operative pain control following Cesarean Section

A multicenter, randomized, double-blind, Placebo-controlled, parallel group study of Intravenous Methylnaltrixone (MOA-728) for the treatment of post-operative Ileus after Ventral Hernia Repair-sponsored by Wyeth Laboratory

Department of Preventative Medicine

Research Overview

For the year of 2011, we had funding support for research through the Department of Defense for the study of prostate cancer in African Americans, Memorial Sloan-Kettering Cancer Center for our multiple myeloma studies, Nebraska cigarette tax funds, the Starr Foundation, and the Heider Endowed Chair in Cancer Research. This has made it possible for our department and its Hereditary Cancer Center to accrue hereditary cancer families of virtually all varieties and enabled us, our colleagues at Creighton, and collaborators both nationally and internationally, to utilize DNA, pathology, and well-described cancer family histories, for highly effective basic science and clinical translational research studies.

All of the department’s research activity is under the direction of Henry T. Lynch, M.D.
Specific Areas of Research

Multiple Myeloma

Our most significant finding from the past year in multiple myeloma came in collaboration with Dr. Steven Lipkin from Cornell Medical Center. Findings of paraprotein-8 segregating among affected family members indicate that it might well be involved in a general pathogenic mechanism. Other collaborations that continue to be important are with Geraldine Schechter, M.D., from Washington VA Medical Center; Diane Moglia, M.S., C.G.C., from Good Samaritan Hospital Medical Center in New York; and Sandra Grass, M.D., and colleagues in Germany.

Prostate Cancer Genetics in African Americans

We, in collaboration with Jackson State University, Jackson, Mississippi, have been awarded a grant by the Department of Defense to study the genetics of prostate cancer (PC) among African Americans (AAs). AAs have a more than two-fold increased lifetime risk for PC and their response to conventional management is also less effective. In addition to garnering a better understanding of PC’s etiology among AAs, we believe that this knowledge will prove useful for screening and management.

Hereditary Breast-Ovarian Cancer (HBOC) Syndrome

In collaboration with San Ming Wang, M.D., at UNMC, we have studied exomes in our HBOC families. This collaboration also involves Dr. Lipkin; Kenneth Offit, M.D., Memorial Sloan-Kettering Cancer Center; and David Goldgar, Ph.D., University of Utah School of Medicine.

Lynch Syndrome

Our study of a 700-member Lynch syndrome family wherein we have identified the EPCAM germ line mutation has been published in the American Journal of Gastroenterology. Discovery of the mutation occurred in collaboration with Drs. Stephen Thibodeau and Douglas Riegert-Johnson of the Mayo Clinic. With this discovery, mutation-positive family members can receive targeted colonoscopic screening. A collaboration being initiated with Megan Hitchins, Ph.D., of Sydney, Australia, will investigate a mutation she discovered that shows dominant transmission of a soma-wide highly mosaic MLH1 methylation and transcriptional repression linked to a particular genetic haplotype in Lynch syndrome.

Familial Colorectal Cancer Type X

Familial colorectal cancer type X (FCCTX) is a recently described disorder that is similar to Lynch syndrome in that it shows familial clustering of colorectal cancer, but does not involve the extracolonic cancers integral to Lynch syndrome. It is apparently not caused by a mutation in a mismatch repair gene as is true of Lynch syndrome, and its molecular genetic aspect is yet to be elucidated. An NIH R01 grant is being prepared for submission in October 2012 aimed at utilizing exome sequencing to search for a molecular genetic basis to FCCTX. Dr. Wang will again be involved in exome sequencing of DNA from families accrued from our own extensive registry of colorectal cancer-prone families, as well as other families through Dr. Xavier Llor at University of Illinois, Dr. James Church at the Cleveland Clinic, and Drs. Lindor and Thibodeau at the Mayo Clinic.

Division of Allergy/Immunology

Overview:

The Division is primarily interested in pathophysiology of airway diseases and the development of novel therapies for these diseases. The division is also engaged in collaborative work with Drs. Yaping Tu and Peter Abel in the Department of Pharmacology. It employs animal, in vitro and human models for this work.
Specific Summary of Recent Work:

Drugs targeting individual G protein–coupled receptors are used as asthma therapies, but this strategy is limited because of G protein–coupled receptor signal redundancy. Regulator of G protein signaling 2 (RGS2), an intracellular selective inhibitor of multiple bronchoconstrictor receptors, may play a central role in the pathophysiology and treatment of asthma and COPD. We defined functions and mechanisms of RGS2 in regulating airway hyperresponsiveness (AHR), the pathophysiologic hallmark of asthma and an important feature of COPD. Real-time PCR and Western blot were used to determine changes in RGS2 expression in ovalbumin sensitized/-challenged mice and mice exposed to cigarette smoke. We also used immunohistochemistry and real-time PCR to compare RGS2 expression between human asthmatic and control subjects. The AHR of RGS2 knockout mice was assessed by using invasive tracheostomy and unrestrained plethysmography. Effects of loss of RGS2 on mouse airway smooth muscle (ASM) remodeling, contraction, intracellular Ca\textsuperscript{2+}, and mitogenic signaling were determined in vivo and in vitro. We found that RGS2 was highly expressed in human and murine bronchial epithelium and ASM and was markedly downregulated in lungs of ovalbumin-sensitized/-challenged mice and cigarette smoke. Lung tissues and blood monocytes from asthma patients expressed significantly lower RGS2 protein (lung) and mRNA (monocytes) than from non-asthmatic subjects. A similar finding was obtained in smokers with AHR. The extent of reduction of RGS2 on human monocytes correlated with increased AHR. RGS2 knockout caused spontaneous AHR in mice. Loss of RGS2 augmented Ca\textsuperscript{2+} mobilization and contraction of ASM cells. Loss of RGS2 also increased ASM mass and stimulated ASM cell growth via extracellular signal regulated kinase and phosphatidylinositol 3-kinase pathways. Thus, we identified RGS2 as a potent modulator of AHR and a potential novel therapeutic target for asthma.

Department of Medicine: Division of Cardiology

Since its founding in 1961, the Division of Cardiology has been dedicated to being a leader in the fields of cardiovascular research, clinical education, early detection and prevention of cardiovascular disease, and pioneering the use of new cardiac procedures and therapies. Over the past 50 years, The Cardiac Center has served more than 185,000 patients and trained over 130 cardiologists.

Our team of cardiologists, nurses, pharmacists, exercise physiologists and healthcare professionals are specialists in the diagnosis and treatment of cardiovascular disease. We will work closely with primary care physicians to provide the highest quality of care and state-of-the-art diagnostic procedures.

Services at The Cardiac Center include: Physician evaluation and management, electrocardiography (including atrial fibrillation ablation), x-ray, exercise testing, echocardiograph (including transesophageal), implantable Cardiac Defibrillator (I CD), angioplasty, pacemaker management, medication management, heart failure management, event recorder monitoring, cardiac catheterization (diagnosis and intervention), exercise testing, laboratory services, risk reduction, cardiac prevention and rehabilitation, individualized weight management consultations, smoking cessation, worksite wellness programs, and research opportunities.

The Division of Cardiology, under the direction of Dennis Esterbrooks, MD, continues to build upon its commitment to provide superior clinical services, participate in sponsored clinical research and take part in community-focused intervention programs.

Research

The Division of Cardiology builds upon its clinical services by participating in sponsored clinical research, supporting faculty and fellow-initiated investigations, and offering community focused intervention programs under the direction of Michael Del Core M.D., and Aryan Mooss, M.D., Medical Directors of Research, and Tammy Bums, Pharm.D., Administrative Manager. The Cardiac Center initiated multiple
new research studies during 2011, primarily phase III and IV pharmaceutical and device trials and registries, as well as investigator-initiated research.

Interventional/ Acute Coronary Syndrome Trials

Several of the clinical trials are focused on Acute Coronary Syndrome (ACS). The goal of these studies is to better define the best possible standard of care in the treatment of patients with unstable angina, Non-ST elevation myocardial infarction (MI), and ST elevation MI. In addition, the Cardiac Center is participating in carotid stent registries to better understand the outcomes related to carotid stenting.

Prevention Trials

Multiple global outcome studies are in progress at the Cardiac Center to improve efforts toward secondary prevention post ACS. In addition to secondary prevention trials, the Cardiac Center is also participating in studies to evaluate cardiovascular outcomes related to new treatments for diabetes.

Non-invasive, Anticoagulation and Electrophysiology Trials

The Cardiac Center has continued to be active in anticoagulation clinical trials in atrial fibrillation patients. Several studies have been completed and are currently underway to improve treatment in this arena.

The Cardiac Center also participated in several studies in patients with heart failure. Studies have looked at patients with preserved systolic function, acute decompensated heart failure, and chronic heart failure with reduced ejection fraction.

A growing area in research at the Cardiac Center is in the area of electrophysiology. Several studies have been conducted in this area, with a consortium of new studies in the start-up phase.

The Clinical Research Area continues to promote a team approach to research, uniting investigators and staff with their particular areas of interest. Our experienced team continues to seek out and conduct investigator initiated and clinical research trials that will shed more light on the prevention and treatment of cardiac disease.

Education

Funded Programs in Minority Cardiovascular Risk Prevention

The Cardiac Center recognized a need to provide educational and preventive programs to the local community and responded with multiple initiatives. These programs enhance Creighton's visibility in the Omaha community and establish the university as a partner willing to share its resources to improve health care in the minority community.

Benson Community Health Center

In November 2005, the Cardiac Center of Creighton University Medical Center and Creighton University established the Creighton Community Health Center (CCHC) in an effort to enhance educational opportunities for Creighton students, improve health care services to local underserved populations and advance the science directed toward reducing, eliminating, or preventing health disparities in minority and underserved populations. In March 2009, CCHC began a collaborative with Charles Drew Health Center (CDHC) to create the Benson Community Health Center (BCHC). Through this venture, Creighton University staff offered health promotion and educational activities to community members, and community service and practical opportunities to Creighton University allied health students. CU staff provided cholesterol, blood glucose, and blood pressure screenings both on- and off-site, while CDHC provided outpatient medical care encompassing curative and preventative medicine for both children and adults.
**Health Fairs**

The Creighton staff members at BCHC have provided blood pressure, cholesterol, and glucose screenings to over 1500 community members at various organizations throughout the north Omaha metro area. Organizations range from non-profit community service organizations to community centers and schools to local churches. Although health fair participant demographics vary, most of those served are African American women over the age of 40 years.

**Exercise and Education Classes**

Exercise and educational opportunities remain the most popular on-site activities offered by BCHC. Through mid-2012, Creighton staff members expanded exercise opportunities to include a walking group, an exercise-only class, and a 12-week exercise and education class, and a higher intensity circuit class. Regular community health presentations by Creighton faculty and professional students were conducted as well. These highly requested, well attended one-time sessions were offered between six and ten times throughout the year.

**Tobacco Prevention and Cessation**

**Tobacco Prevention Coalitions**

Creighton is an active member of the Metro Omaha Tobacco Action Coalition (MOTAC). This project is supported by grant dollars from Tobacco Free Nebraska, a division within Nebraska Health and Human Services System. The goals of the grants were to reduce exposure to secondhand smoke in the workplace, home, and house of worship, and to prevent youth initiation of tobacco use through education. The health educator has coordinated activities surrounding tobacco prevention for youth and adults over the past year. The health educator has participated in recognizing multiple businesses during this period for their tobacco free building and/or campus status.

**Tobacco-Free Creighton**

On July 1, 2008, Creighton University became the first Jesuit-Catholic campus to be tobacco-free. Father John P. Schlegel, S.J., President, appointed Dr. Syed Mohiuddin, Richard W. Booth, M.D., Endowed Professor of Cardiology and chair of the Department of Medicine, to chair a workgroup to address the issues associated with the implementation of a tobacco-free policy at Creighton University. Dr. Mohiuddin oversaw the implementation of a successful tobacco-free pilot at The Cardiac Center. Our tobacco treatment specialist served as a member of the wellness committee and has assisted the group with ongoing efforts to keep Creighton tobacco free.

**Tobacco Cessation Program**

Commit to Quit, Creighton's premier tobacco cessation program, was developed in 1999 and is responsible for helping hundreds of tobacco users end their addiction to nicotine. Commit to Quit is available to corporations on-site, during the workday to offer businesses the chance to help employees lead healthier lives. The Cardiac Center is contracted to provide tobacco treatment services to employees at over 25 worksite locations in Omaha and surrounding communities. Commit to Quit continues to offer cessation services to the general community as well. Commit to Quit has served over 500 participants to date.

**Grants**

Within the research section, we assisted in the development and technical assistance of 13 grants during 2011. A complete list of grants can be found in a later section of this document.
Department of Medicine: Division of Dermatology

Overview

During the calendar year 2011, the Division of Dermatology conducted three clinical trials. The main focus of these trials was on psoriasis.

Specific Areas of Research

The Division of Dermatology received funding for two plaque psoriasis studies. In both studies, patients were treated for moderate to severe plaque psoriasis. Psoriasis is a disease with multiple dimensions. Area and severity on skin areas were studied in a subcutaneously administered treatment (AIN457) following the severity index (PASI). The other study was a safety study for long term use of the human monoclonal antibody against IL-12. Both studies were conducted simultaneously with satisfactory enrollment as well as outcomes.

School of Nursing

School of Nursing faculty members participate in areas of research that address health promotion, clinical practice, and the scholarship of teaching and learning. Faculty members’ studies are supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute, Agency for Healthcare Research and Quality, Community Pharmacy Foundation, and Creighton Health Futures Foundation. Faculty members also assist doctoral, master’s, and bachelor’s degree students in mastering competencies for evidence-based practice. Faculty members published 25 articles and book chapters and presented 61 scientific papers and posters at regional, national and international conferences over the past academic year.

Marlene Wilken, principal investigator, is in the second year of a two-year quasi-experimental study comparing Diabetes self-management (DSME) outcomes in American Indians with DM2. Funded by the National Institute of Diabetes, Digestive, and Kidney Diseases, the research question is whether participants who receive the DSME and participate in the culturally appropriate Talking Circle have better outcomes than those participants who receive only the classroom DSME. A qualitative analysis of the Talking Circle audio tapes will seek to identify themes that affect diabetes self-management. Dr. Wilken also published research on the use of Miracle Fruit to mediate taste changes in individuals undergoing chemotherapy and compliance of health professionals in testing children’s blood lead levels.

Co-Investigators Joan Lappe and Ann Laughlin continue on a National Institutes of Health funded grant to determine if increasing the intake of dairy foods to recommended levels in 13 and 14 yr. old females with low calcium intake will decrease body fat gain compared to similar females who continue with their low calcium intake. Subjects in the intervention group agree to consume at least 1200 mg of calcium per day for one year and the effects of dairy foods on weight and bone health are studied over the course of this year.

Amy Abbott and Cindy Costanzo are expanding their expertise in health disparities as participants in the Health Disparities and Research Training Program sponsored by the Minority Health and Health Disparities Research Program at the University of Alabama at Birmingham. Dr. Abbott also serves as a faculty member in Creighton’s Center for Health Services Research and Patient Safety, and is conducting and contributing to various collaborative research studies on information technology, personal health records, privacy issues related to electronic health records (EHRs), and consumer education tools. Her other research interests include symptom management and Interprofessional education.

Catherine Carrico and Amy Yager completed Doctor of Nursing Practice (DNP) degrees in 2011, and as part of the DNP program, conducted practice-related projects. Dr. Carrico explored the postpartum TDAP
status of women and close infant contacts in the prevention of pertussis transmission to infants. Dr. Yager created a social networking site (Business Facebook site) that provided current statistics on sexually transmitted infections (STIs), information on free clinics for STI testing, and videos about the dangers of STIs, myths about STIs, etc. Visitors to the site could post questions for a health care professional, and Dr. Yager answered questions. An evaluation of the Teen Sexual Health Information Facebook site was completed and the strengths included consumers’ interest in the information, and the ease with which information could be accessed.

School of Pharmacy and Health Professions

The faculty of the School of Pharmacy and Health Professions guide the development of excellence in the clinical professions of occupational therapy, pharmacy, and physical therapy. The School also grants a degree in Emergency Medical Services. The School consists of four academic departments: Occupational Therapy, Pharmacy Practice, Pharmacy Sciences, and Physical Therapy. These departments work collaboratively and collectively to achieve excellence in these professional program offerings. The scope of research is broad – with active research programs and projects in the biomedical sciences, health services research, clinical research, and educational research areas of emphasis. Interdisciplinary and inter-professional approaches characterize the school’s research models and culture throughout the scope of research. The faculty is composed of both basic scientists and clinician scientists who provide a framework for basic, translational and applied research opportunities. Faculty engage in national, regional, state-wide and local research initiatives – with several holding appointments on federal grant review panels and providing consultation and service for agencies within the United States Department of Health and Human Services National Institutes of Health (NIH), Health Resources Services Administration (HRSA), Agency for Healthcare Research and Quality (AHRQ), Indian Health Service (IHS), as well as the National Science Foundation (NSF) and the Department of Defense (DoD).

Office of Research

The School’s Office of Research was established in mid-2004 to provide faculty support and services to assist faculty with quality and productivity in research efforts. The office provides faculty, staff, and students opportunities for the utilization of up-to-date technologies in its computer laboratory and conference areas. These technologies allow researchers to come together to share ideas and more rapidly produce proposals. The office continues in strategic efforts to engage community and academic partners in research opportunities with Creighton faculty. Individualized efforts are made with newer faculty members who have expressed great interest and promise in pursuing research. The Office of Research provides core leadership to the development of the SPAHP Research Student Program and supports the School’s work in campus wide efforts of University Research Day and St. Albert’s Day.

Research Funding and Cross Campus Collaborations

Both internal and external funding has been received by the faculty in the broad research categories of biomedical sciences, health services research, clinical research, and educational research. In the January–December 2011 reporting period, 21 externally funded research and training grant awards and two internal grant awards through the Creighton University Health Futures Foundation were attained by faculty as primary investigators. The total award amount for this period was $1,641,239. There were 2 funded projects where a SPAHP faculty member served as principal investigators and worked with co-investigators from other schools.
**Student Research**

- Graduate Student Research. The school has both undergraduate and graduate students actively engaged and mentored by faculty in research. At present 14 students are enrolled in the Masters of Science Program in Pharmaceutical Sciences. A research thesis is required for the partial fulfillment of the requirements of the program. The research areas include pharmaceutics, medicinal chemistry, immunology, pharmacology, anatomy, toxicology and pharmacokinetics. The specific areas of interest include drug delivery systems, medicinal chemistry, regulation of T helper cells, pharmacology of the eye and TCDD toxicity. To date, 25 students have graduated from the program.

- Clinical Doctorate Student Research. Research project completion is a required activity within the Doctor of Occupational Therapy and Doctor of Physical Therapy programs, and encouraged in the Doctor of Pharmacy Program. The faculty provides mentorship and guidance in skills Faculty development for all forms of research, with common areas of emphasis being service-learning, reflective practice, and applied outcomes research.

- Student Research Program. Students enrolled in the Occupational Therapy, Pharmacy and Physical Therapy professional degree programs were given the opportunity to competitively apply for either a summer or academic year faculty-mentored research experience. This experience was planned with a faculty member who gave oversight and guidance to the students' research skills development by engaging the student in components of active, on-going research projects. Between January – December 2011, 12 students were each awarded $3,000 stipends to participate in either the summer or academic year programs. Students from the summer and academic year research program, along with students from Occupational Therapy, Pharmacy Science and SPAHP graduate students participated in the university-wide St. Albert's Day student research forum which provided them the opportunity to present their research findings to a campus-wide audience through posters and podium presentations.

**Creighton Center for Health Services Research and Patient Safety (CHRP)**

The Center for Health Services Research and Patient Safety (CHRP) was formed in 2004 to promote and sustain patient safety and quality through the conduct and translation of health services research to education and practice. The program brings together researchers and scholars for interprofessional collaboration and faculty and student development university-wide. Specific areas within the safety and quality core include new and emerging technological influences on safety, the effects of health care financing, relationship of costs of pharmaceuticals and treatments, social and behavioral influences on care, access and disparities issues, and models of care delivery in an interdisciplinary context.

The program was launched within the School of Pharmacy and Health Professions (SPAHP) and is funded through external grants. It has grown to include university-wide representation. Years 1 and 2 focused on establishing key technology infrastructure and interdisciplinary education and development and establishing and expanding external community, private and government relationships. Subsequent years focused on an intensive research development process for faculty through both training and the conduct of research, provision of education to students, practitioners and the community, and local, state and federal service related to the areas of patient safety and health care quality. Scholarly productivity has been significant, with over 124 publications, 223 presentations, and 20 media releases.

Between January – December 2011, CHRP continued to support its interdisciplinary collaboration through the submission of 4 grant proposals ($853,783) resulting in the funding of 2 grants totaling $543,783. CHRP has been successful in developing interdisciplinary research teams and expanding partnerships in Nebraska and surrounding states. Collaborative networks with the Schools of Nursing, Dentistry, Medicine, Arts and Sciences, Business Administration, and Law have formed as the program has matured. This growth is from aggressive networking with individuals who have the expertise and interests.
consistent with the health services research mission of this program and who expect to have mutually beneficial success from involvement in this initiative.

Between January – December 2011, CHRP offered university wide research skills development for faculty, staff, and students through its Meet the Researcher Series presentations. This series brings skills, methods, and networking relationships to others on campus and across the country through audio and web-aided live presentations on a monthly basis. Six seminars were presented by Creighton faculty members and nationally known researchers. One seminar was offered by students involved in research projects with CHRP faculty. Topics included: electronic records with patient portals; multi-center randomized clinical trials; strategies to close the feedback loop in the ambulatory setting; a case demonstration of epidemiologic research methodologies; and team science rigor in qualitative and mixed research design. Attendance for these presentations has been outstanding with over 125 faculty, staff, and students participating from the schools of Pharmacy and Health Professions, Nursing, Dentistry, Medicine, and Arts and Sciences.

CHRP was formed to provide the infrastructure and resources necessary to identify external funding sources, prepare and submit grant applications, and to maintain project management through staff and technology support to achieve future growth. CHRP maintains the data entry and analysis center with four workstations and installed software applications for statistical and qualitative data analysis. The repository of database and research tools is continually updated and expanded. (See www.chrp.creighton.edu for a complete listing). The CHRP computer lab is equipped with a variety of analytic software programs to assist end users in data management. These programs include: Microsoft Office, SPSS, SPSS Text Analysis, SAS, ArcGIS, Atlas.ti, and MPlus. Additional programs are evaluated and installed based on special needs projects. The computer lab is available and accessible to all students, faculty and staff in the school. Assistance is available on request.

Office of Interprofessional Scholarship, Service and Education (OISSE)

The Office of Interprofessional Scholarship, Service and Education (OISSE) was formed in 2001 and is responsible for planning, organizing, and implementing educational, service, and scholarly projects related to interprofessional community engagement in the School of Pharmacy and Health Professions. OISSE maintains a long-standing partnership with the Omaha and Winnebago Tribes addressing health disparities and providing students from across the health sciences with rural, cross-cultural, interprofessional learning experiences. Through the partnership with the Winnebago Tribe of Nebraska, a clinical contract was awarded to the School by the U.S. Department of Health and Human Services, Indian Health Service to co-fund faculty clinicians who sustain physical and occupational therapy services at the US Public Health Service facility in Winnebago, Nebraska.

Since 2005, OISSE’s community engagement model has expanded to coordinate local opportunities in the Omaha metropolitan area, as well as assist with international initiatives in the Dominican Republic and China. The OISSE infrastructure recognizes Faculty Associates across the health science programs and various community stakeholders interested in interprofessional community engagement. Thirty-eight Creighton faculty members from physical therapy, occupational therapy, pharmacy, nursing, medicine, dentistry and the Health Sciences Library, in partnerships with community members, collaborate on health promotion and disease prevention initiatives across the lifespan to meet authentic community needs, provide student learning opportunities, and disseminate initiatives via scholarly products.
Department of Occupational Therapy

The Department of Occupational Therapy consists of three administrative assistants, 134 on-campus, 28 distance entry level OTD students, and 43 Post Professional OTD students, 18 faculty, including 17 faculty with doctoral degrees and 1 clinical faculty holding a master's degree. Faculty engage in a variety of teaching, service and scholarly activities each year. Faculty are engaged in the following areas of scholarship productivity:

- Scholarship of Practice: Increasing occupational therapy services in rural areas, interprofessional geriatric care, error reporting and client safety, outcomes of physical agent modalities, Assessment of Stroke Rehabilitation in Nebraska, etc.
- Scholarship of Teaching and Learning: Outcomes of service learning activities at both national and international levels; and
- Scholarship of Engagement: Health disparities, migrant workers, occupational patterns and disability, interprofessional care of the Native Americans through participation in OISSE grants and contracts.

Extramural funding sources for current research projects include AHRQ Research Infrastructure Program: Phase II, Harvard Immigration Project, CDC via the MRFASTC program, CIMRO of Nebraska-Wide River TEC, and National Association of Boards of Pharmacy and AACP. Intramural funding was provided through faculty grants from the Office of Academic Excellence and Assessment and Creighton President Research Fund.

Publication productivity consists of: 13 peer reviewed journal articles, 7 book chapters, 3 books edited and authored by faculty. Faculty also presented at professional conferences at regional and national levels.

Annual professional development plans for each faculty member include at least one goal targeted at scholarship development and productivity. Faculty continue to garner support from institutional infrastructures such as CHRP and OISSE.

Department of Physical Therapy

The Department of Physical Therapy is composed of 46 faculty, 4 residents, 179 students (177 entry level program; 2 transitional program) and 2 staff. Fifteen faculty are core as defined by the Commission on Accreditation in Physical Therapy Education program accreditation standards. Nine core faculty have teaching-research classification appointments. One of the faculty is Dean, Graduate School and University College/Summer Sessions and Associate Vice President for Research, Academic Affairs. Six core faculty have clinician-educator classification appointments. The remaining faculty have contributed-service faculty appointments.

During 2011, the faculty produced 21 peer-reviewed publications as primary or co-author. Faculty made 47 presentations of research and scholarship at international, national, and regional conferences. Nine of the faculty were funded as principal or co-investigators for a total of 3.5 million dollars in grant awards of which 1.8 million was from the NIH. Other sources of funding included the Foundation for Physical Therapy, American Physical Therapy Association, and the Health Future Foundation.

The core faculty have identified four areas of emphasis for scholarship:

- Community Engagement
- Health Services Research
Teaching/Learning

Rehabilitation Sciences with an emphasis on movement disorders

The Community Engagement area is supported by the Office of Interprofessional Scholarship, Service and Education. Work in this area has included Native American health and student immersion in domestic and international underserved environments. Faculty research has addressed childhood obesity in south Omaha, a diverse, urban community. The Health Services research area is supported by the Creighton Health Services Research Program and has focused on patient safety, building a health services research infrastructure and professional discipline/ malpractice. The Teaching/Learning research area is supported by the Office of Faculty Development and Assessment and is focused on the scholarship of teaching. The Rehabilitation Science Research Laboratory is a department initiative with a focus on investigating the effects of therapeutic interventions on movement dysfunction with a primary focus on the adult population. Active areas of study include the biomechanical impairments, functional limitations and therapeutic strategies associated with neurologic disorders (such as those secondary to Parkinson’s Disease, diabetes and peripheral vascular disease) and the role of peripheral sensory systems in the rehabilitation of walking for people with amputations.

Department of Pharmacy Practice

The Department of Pharmacy Practice is primarily responsible for the clinical education of students enrolled in the Doctor of Pharmacy program. The large majority of the 50 faculty are clinician scientists whose research efforts are integrated within their clinical practice sites. Faculty maintain practices at CUMC and affiliated clinics, hospitals in the Alegent system, Methodist Hospital, Omaha and Lincoln VAMCs, and Bryan LGH Medical Center in Lincoln. Our clinical faculty established collaborative relationships with faculty in the Departments of Medicine and Family Practice for a number of general and specialty clinics, the Department of Family Practice, and the Department of Psychiatry for a number of general and specialty clinics. The Pharmacy Practice Department has established and maintains nine maintained residency and fellow positions in pharmacy practice that complete their training throughout CUMC, Bergan Mercy Medical Center, and Immanuel Medical Center. During 2011, the faculty produced 142 peer-reviewed publications as primary or co-author.

The Center for Drug Information & Evidence-Based Practice (CDI-EBP) supports three distinct Drug Information services, including practices at the Health Sciences Library, Immanuel Medical Center and Creighton University Medical Center. Each of these sites provides institutional support, as well as serving as a training location for rotation students. Four full-time Drug Information Specialist faculty are responsible for supporting the CDI-EBP. Additionally, collaborative efforts to provide evidence-based medicine education to medical residents at CUMC are underway. The CDI-EBP has recently entered into a contract with an industry publishing partner for medicine, nursing, pharmacy and allied health fields, to provide content for a new information product being developed.

Research and scholarship emphases are in educational assessment and outcomes research, clinical outcomes research, nanoparticles containing three antiretroviral agents, infectious diseases, clinical research in chronic disease management areas such as diabetes, dyslipidemia, and public health research related to immunizations and disease prevention. Recent progress in the area of nanoparticle formation and production has been made that holds promise for the delivery of HIV drugs. This work is possible through collaborations between scientists in pharmacy practice, Department of Biology, and Medical Microbiology and Immunology at Creighton University and funding from a NIH R56 award. Clinical outcomes research in the areas of aspirin resistance in women, clopidogrel resistance in coronary patients, and clinical management of diabetes by pharmacists are examples of some active research by the clinical scientists in the department.
Department of Pharmacy Sciences

The Department of Pharmacy Sciences has 20 faculty who are either PhD only (13), PharmD and PhD (3), PharmD only (3), or B.S Pharmacy and MBA (1) trained. There is a diversity of backgrounds in the department that includes pharmaceutics, pharmacology, toxicology, medicinal chemistry, health services research and administration, educational, behavioral and social and administrative sciences in pharmacy. The department is home to the M.S. in Pharmaceutical Sciences. Faculty in the basic sciences have engaged in cross collaborations within Creighton University and at other universities. Drug and dosage pre-formulation, characterization of the solid-state properties of drugs and delivery systems, drug delivery system design using nanotechnology, pharmaceutical analysis, and nutraceuticals are funded research within the department. Controlled deliveries of therapeutic protein and peptides in their conformational stability and biological activity from using smart polymer based delivery system is an active area of work. Another area is transdermal drug delivery using chemical enhancers as well as physical enhancers like iontophoresis, electrooeration, sonophoresis while preserving skin reversibility, as well as percutaneous absorption of chemicals (toxicants, pollutants) and associated dermatotoxicity and skin irritation. Formulation and pre-clinical drug development and testing are also being conducted for the pulmonary delivery of active pharmaceutical ingredients and imaging agents for the identification, characterization, and treatment of both lung and systemic conditions.

Research related to diseases and conditions under study include cancers, asthma, glaucoma, infectious disease, addictions such as cigarette smoking, and molecular mechanism of normal embryo and fetal development. Research focuses on the role of TH-1/TH-2 cytokine imbalance to the etiology of asthma and allergic disease. These investigations will provide further information about treatment approaches that may be effective in the disease. Faculty are investigating the effect of cigarette smoke extract (CSE) on the conformational stability and biological activity of a model protein lysozyme, so that they may understand the mechanism of genesis of the diseases caused by smoking. Ocular diseases may have new treatment opportunities through the research of faculty who are studying the role of isoprostanes on neurotransmitters in ocular tissues (NIH funded research area). Research is active in the synthesis, in vitro and in vivo biological evaluation of bicyclic octahydroisoquinolines as β2 selective adrenoceptor agonists and of the synthesis and biological evaluation of bicyclic hexahydroporphines as an intraocular pressure lowering and neuroprotective agent. Another research focus is utilizing computational methodology to identify lead biologically active compounds and employing both solid and solution phase chemistry for synthesizing them. Other research focuses on the control and regulation of gene expression during embryonic development. The role of Hox genes in the development of the craniofacial region of the embryo is researched to better understand how various embryonic structures develop, how the coordination of gene activities in both time and space is critical, and how disruption of these events can lead to birth defects. These and other accomplishments have been achieved through collaboration and work with the state EPSCoR (Experimental Program to Stimulate Competitive Research) program, the University of Nebraska and various departments (Chemistry, Biomedical Sciences, and others) within Creighton University.

Faculty with emphases in the behavioral, social, and administrative sciences conduct much of their work through the support and collaborative infrastructure of the Creighton Center for Health Services Research and Patient Safety (CHRP). Funded research efforts in CHRP include the study of the impact of health information technologies on patient safety in rural outpatient clinics and community pharmacies. Research has occurred with a core group of faculty in the study of pharmacy benefits management policies and practices, pharmacy practice models – such as mail order services and therapeutic drug monitoring services, and drug therapy adherence and compliance. Other research is focused on organizational theory, workforce and culture issues, and teamwork skills related to patient safety. One project is focused on a longitudinal effort in educational research related to pharmacy and professionalism development. Work is also being conducted in the area of educational technologies and student learning.


Wright, W. M. Musings on Wisdom and Becoming Wise. *Weavings, 26*(3), 41-47.


**College of Business**


School of Dentistry


### School of Law


### School of Medicine


Bathla, L., Harris, A., Davey, M., Sharma, P., & Silva, E. (2011). High resolution intra-operative two-dimensional specimen mammography and its impact on second operation for re-excision of positive


immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA2LEN) article. *Journal of Allergy and Clinical Immunology*, 127(1), 49.


Zhang, H., Lu, W., Zhao, Y., Rong, P., Cao, R., Gu, W., et al. (2011). Adipocytes derived from human bone marrow mesenchymal stem cells exert inhibitory effects on osteoblastogenesis. *Current Molecular Medicine, 11*(6), 489-502.


**School of Nursing**


Zhang, H., Lu, W., Zhao, Y., Rong, P., Cao, R., Gu, W., et al. (2011). Adipocytes derived from human bone marrow mesenchymal stem cells exert inhibitory effects on osteoblastogenesis. Current Molecular Medicine, 11(6), 489-502.

School of Pharmacy and Health Professions


Grants

College of Arts and Sciences


Gabel, J. [Investigator]. Multi-wavelength studies of mass outflows in active galactic nuclei. National Aeronautics and Space Administration — $8,784 — [1 September 2011-30 June 2012]


Habash, M. 2010-2011 Fulbright Visiting Scholar (Post-Doctoral) Grant for Research at Yarmouk University in Irbid, Jordan. Research was conducted on unpublished Latin and Greek inscriptions found in Northern Jordan.


Schalles, J. F. [Investigator]. Sending graduate student John Olley to collaborate with Dr. Alex Gilerson at the City College of New York. National Aeronautics and Space Administration — $641 — [1 March 2011-31 March 2011].


Van Dijk, K. [Investigator]. RII Track-1 NCAAB undergraduate lab enhancement project. National Science Foundation/EPSCoR — $24,740 — [1 October 2010-30 September 2015].


School of Dentistry


Latta, M. A. [Investigator]. HFF program: Start-up award for Dr. Alvin Wee. Health Future Foundation — $81,380 — [1 July 2011-30 June 2013].

Latta, M. A. [Investigator]. Laboratory evaluation of localized wear of resin restorative materials. 3M Dental Products Division — $13,500 — [28 October 2010-31 January 2011].

Latta, M. A. [Investigator]. Marginal quality and enamel microleakage of conventional and low shrinkage stress restorative systems. Dentsply — $1,925 — [1 January 2009].


Latta, M. A. [Investigator]. Student dental research support. Iowa Dental Association — $500 — [15 January 2004].


Wee, A. [Investigator]. Rationale for late stage diagnosis in oral cancer (Oral lesion interview study). National Institutes of Health — $79,170 — [1 April 2011-31 August 2012].

School of Law


School of Medicine

Abel, P. W. [Investigator]. Short course: Integrative and organ systems pharmacology. University of Nebraska Medical Center / NIH-National Institutes of Health — $30,000 — [1 May 2010-30 April 2011].


Akhter, M. P. [Investigator]. Effect of sclerostin and/or DKK-1 antibodies in a rat spontaneous/inducible periodontal disease model. Amgen, Inc.— $28,357 — [6 June 2011].


Arouni, A. [Investigator]. Re-Ly-able long term multicenter extension of dabigatran treatment in patients with atrial fibrillation who completed the Re-Ly trial and a cluster randomized trial to assess the effect of a knowledge translation intervention on patient outcomes. Boehringer Ingelheim Pharmaceuticals, Inc. — $6,980 — [31 December 2008].

Babcock, N. K. [Investigator]. Double-blind, randomized, multicenter, dose-ranging study to evaluate the safety and efficacy of lusedra (fospropofol disodium) as an intravenous sedative for diagnostic or therapeutic colonoscopy in adult special populations. Eisai Medical Research, Inc.— $1,603 — [1 April 2010].


Beisel, K. [Investigator]. Functions and disorders of K channels in the inner ear. National Institutes of Health — $74,620 — [1 April 2011-31 March 2012].


Bhatia, S. K. [Investigator]. Double-blind, placebo-controlled study of cariprazine (RGH-188) as adjunctive therapy in major depressive disorder (RHG-MD-71). Forest Research Institute, Inc.— $13,369 — [1 April 2009].

Bhatia, S. K. [Investigator]. Long-term, open-label extension study of escitalopram in adult patients with major depressive disorder. Forest Research Institute, Inc.— $4,021 — [1 July 2008].


Bockman, C. S. [Investigator]. Environmental experience, nicotine acetylcholine receptors and behavior. State of NE-LB595 — $40,000 — [1 July 2010-30 June 2012].


Casale, T. B. [Investigator]. Ramdomized, multicenter, parallel group, double blind, study to assess the safety of QMF twisthaler (500/400) and mometasone furoate twisthaler (400) in adolescent and adult patients with persistent asthma. Novartis Pharmaceuticals Corporation — $19,322 — [1 July 2009].
Casale, T. B. [Investigator]. Randomized, double-blind, placebo-controlled, multiple dose phase 2 study to determine the safety and efficacy of AMG 853 in subjects with inadequately controlled asthma. Amgen, Inc.— $6,872 — [1 November 2009].

Casale, T. B. [Investigator]. Randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of SAR231893/REGN668 administered subcutaneously (SC) once weekly for 12 weeks in patients with persistent moderate to severe eosinophilic asthma. Sanofi-Aventis U.S. Inc.— $3,000 — [1 April 2011].


Cavalieri, S. J. [Investigator]. Eurofins clinical isolates submission study. Eurofins Medinet, Inc.— $1,480 — [1 January 2007].


Cavalieri, S. J. [Investigator]. Pathology instruction. Streck Laboratories, Inc.— $1,270 — [1 April 1993].


Chatterjee, A. [Investigator]. Randomized, international, double-blind (with in-house blinding), controlled with gardasil, dose-ranging, tolerability immunogenicity, and efficacy study of a multivalent human papilloma virus (HPV) L1 virus-like particle (VLP) vaccine administered to 16 to 26-year old women. Merck & Company, Inc.— $17,872 — [1 September 2007].


Chatterjee, A. [Investigator] Phase 2, randomized, controlled observer-blinded trial, to assess the safety, tolerability, and immunogenicity of MCV4, TDAP vaccine and RLP2086 vaccine when administered concomitantly in healthy subjects aged 10-13 years of age. Pfizer — $169,250 — [1 October 2011].

Chatterjee, A. [Investigator], Fernandez, C. Phase III, randomized, partially double-blind, active-comparator-controlled, lot-to-lot consistency clinical study to evaluate the safety, tolerability, and immunogenicity of V419 in healthy infants when given at 2,4, and 6 months concomitantly with Prevnar13™ and RotaTeq™. Sanofi-Pasteur Limited/Merck Sharp & Dohme Corp.— $370,700 — [1 July 2011].

Chatterjee, A. [Investigator]. Open-label prospective, pharmacokinetic/pharmacodynamic and safety evaluation of intravenous oseltamivir (Tamiflu) in the treatment of children 1 to 12 years of age with influenza infection. Hoffmann-LaRoche, Inc.— $5,125 — [1 December 2010].

Chatterjee, A. [Investigator]. Fernandez, C. Phase 1/2a, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and vaccine-like viral shedding
Chatterjee, A. [Investigator]. Phase 3, open-label, randomized, multicenter study to evaluate the safety and immunogenicity of ProQuad vaccine when administered concomitantly with Novartis meningococcal ACWY conjugate vaccine to healthy toddlers. Novartis Pharmaceuticals Corporation — $7,380 — [1 November 2007].

Chatterjee, A. [Investigator], Fernandez, C. Phase 3b, randomized, open-label, multicenter study to evaluate the safety and immunogenicity of 2 or 3 doses of MenACWY conjugate vaccine in healthy infants and the effects of a booster dose of MenACWY administered in the second year of life. Novartis Vaccines and Diagnostics, Inc.— $7,868 — [1 December 2010].

Chatterjee, A. [Investigator]. Phase IIb, open multicenter gynaecological extension extension study for follow up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant at their final 580299/008 study visit (Visit 10). GlaxoSmithKline Company — $5,095 — [1 September 2009].

Chatterjee, A. [Investigator], Fernandez, C. Phase III double-blind randomized controlled study to evaluate the safety immunogenicity and efficacy of GlaxoSmithKline biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. GlaxoSmithKline Company — $18,935 — [1 March 2006].

Chatterjee, A. [Investigator], Fernandez, C. Phase III open-label clinical trial to study the immunogenicity and tolerability of V503 (A multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) Vaccine) given concomitantly with Menactra and Adacel in preadolescents (11 to 15 year olds). Merck & Company, Inc. — $6,086 — [1 November 2009].

Chatterjee, A. [Investigator]. Phase III, double-blind, randomized study to evaluate the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine candidate, GSK2282512a (Flu Q-Qiv), compared to GSK Biologicals' trivalent influenza vaccine fluarix administered intramuscularly to children 3 months to 17 years of age; and to describe the safety and immunogenicity of GSK2282512A in children 6 to 35 months of age. GlaxoSmithKline Company — $86,495 — [1 September 2010].

Chatterjee, A. [Investigator], Fernandez, C. Phase III, partially double-blind study to evaluate consistency and immunogenicity of 3 lots of GSK Biologicals' HIB conjugate vaccine 208108 versus Acthib and Pentacel at 2, 4, 6 and 15-18 months of age in healthy infants. GlaxoSmithKline Company — $50,057 — [1 February 2010].

Chatterjee, A. [Investigator]. Phase IIIb open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine Administered Intramuscularly according to a 0, 1, 6-month schedule in healthy female American and Canadian subjects. GlaxoSmithKline Company — $3,000 — [20 February 2009].

Chatterjee, A. [Investigator]. Randomized, international, double-blind (with in-house blinding), controlled with gardasil, dose-ranging, tolerability, immunogenicity, and efficacy study of a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine administered to 16 to 26 year old women. Merck & Company, Inc. — $17,872 — [1 September 2007].

Chatterjee, A. [Investigator]. Safety and immunogenicity of Adacel (TDAP vaccine) compared to Daptacel (DTAP vaccine) as fifth dose booster in children 4 to 6 years of age. Sanofi Pasteur, Inc. — $1,000 — [11 April 2007].


Chatterjee, A. [Investigator]. Unrestricted Educational Grant. InterHealth Nutritionals, Inc. — $5,000 — [1 April 2011].


Chen, X. [Investigator]. HFF program: Chair development (Chen). Health Future Foundation — $51,765 — [1 July 2010-30 June 2013].


Del Core, M. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with history of atherosclerotic disease thrombin receptor antagonist for secondary prevention of atherothrombotic ischemic events (Tra 2P-TIMI). Schering-Plough Research Institute — $4,900 — [1 September 2007].

Del Core, M. [Investigator]. Clinical outcomes study of darapladib versus placebo in subjects following acute coronary syndrome to compare the incidence of major adverse cardiovascular events. GlaxoSmithKline Company — $20,269 — [1 May 2010].

Del Core, M. [Investigator]. Comparison of prasugrel and clopidogrel in acute coronary syndrome (ACS) subjects with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) who are medically managed-the Trilogy ACS Study. Eli Lilly and Company — $90 — [1 June 2008].

Del Core, M. [Investigator]. Inhibition of B-protein kinase C for the reduction of infarct size in acute myocardial infarction (protection AMI). Biogen — $2,058 — [31 December 2008].


Del Core, M. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with a history of atherosclerotic disease thrombin receptor antagonist for secondary prevention? Schering-Plough Research Institute — $24,195 — [1 September 2007].

Del Core, M. [Investigator]. Phase III, double-blind, randomized, placebo-controlled study, to evaluate the effects of R04607381 on cardiovascular (CV) risk in stable chd patients, with a documented recent acute coronary syndrome (ACS). Hoffmann-LaRoche, Inc.— $16,522 — [1 May 2008].
Del Core, M. [Investigator]. Prospective multicenter imaging study for evaluation of chest pain (Promise). National Institutes of Health — $5,000 — [1 October 2010-30 June 2013].

Del Core, M. [Investigator]. Prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent. Harvard Clinical Research Institute — $7,800 — [1 April 2010].

Del Core, M. [Investigator]. Prospective, randomized, multicenter, double-blind trial to assess the effectiveness and safety of different durations of dual anti-platelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention with the cypher sirolimus-eluting stent systems (ELITE). Cordis Corporation — $8,625 — [16 December 2009].


Del Core, M. [Investigator]. Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with unfractionated heparin + eptifibatide, in patients with unstable angina/non st segment elevation myocardial infarction scheduled to undergo an early invasive strategy. Sanofi-Aventis U.S. Inc. — $2,500 — [1 October 2010].

Del Core, M. [Investigator]. Translate-ACS study: Treatment with ADP receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome. Eli Lilly and Company — $5,000 — [1 August 2010].


Drescher, K. [Investigator]. HFF Faculty Development: Impact of neurexophilin on clinical disease in a mouse model of MS. Health Future Foundation — $20,000 — [1 July 2011 - 30 June 2013].


Fernandez, C. [Investigator]. The role of vitamin D supplementation in pediatric asthma. Health Future Foundation — $25,000 — [1 September 2009–31 October 2011].

Fernandez, C., Varman, M.[Investigator]. A phase 1/2a, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and viral shedding of MEDI-559, a live attenuated intranasal vaccine against respiratory syncytial virus in healthy 1 to <24 month-old children. Medimmune — $8,375 — [2 July 2009].

Filipi, C. J. [Investigator]. Augmentation of suture line for durable apposition of gastric walls. SafeStitch, LLC — $25,000 — [1 June 2006].
Fitzgibbons, R. J. [Investigator]. Prospective, randomized, controlled, third-party blinded multicenter evaluation of strattice/LTM in the repair of inguinal (RING) hernias. LifeCell, Inc.— $13,413 — [1 April 2008].

Forse, R. A. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous (IV) ulimorelin administered post-operatively to accelerate recovery of gastrointestinal (GI) motility in subjects who have undergone partial bowel resection. Tranzyme Pharma — $10,931 — [1 April 2011].


Gallagher, J. C. [Investigator]. Open-label, single arm, extension study to evaluate the long term safety and sustained efficacy of denosumab (AMG162) in the treatment of postmenopausal osteoporosis. Amgen, Inc. — $13,788 — [1 October 2007].

Gallagher, J. C. [Investigator]. Randomized, double-blind, multiple dose, placebo-controlled, parallel group, 48-week, study of oral recombinant sct compared to calcitonin nasal spray in postmenopausal osteoporotic women. Unigene Laboratories, Inc.— $7,581 — [1 January 2009].


Goering, R. V. [Investigator]. Chromosomal analysis of staphylococcus auereus isolate by pulsed field gel electrophoresis. Procter & Gamble Company — $5,463 — [1 October 2009].

Goering, R. V. [Investigator]. Drug pool. Wellington Regional Medical Center — $160 — [1 June 2011].


Goering, R. V. [Investigator]. Epidemiological analysis of methicillin-resistant staphylococcus aureus isolates. Trius Therapeutics — $9,000 — [1 November 2010].

Goering, R. V. [Investigator]. Establishment of a PCR ribotyping resource for the molecular characterization of clostridium difficile isolates. Cepheid — $29,600 — [1 July 2011].

Goering, R. V. [Investigator]. Molecular characterization of methicillin-resistant staphylococcus aureus isolates. GlaxoSmithKline Company — $6,975 — [1 July 2011].


Goering, R. V. [Investigator]. Pulse field gel electrophoresis on clinical isolates. Children's Hospital Foundation — $880 — [1 September 2007].


Hansen, L. [Investigator]. Cancer and smoking disease research molecular and cellular mechanisms of carcinogenesis program project: EGFR signaling in skin cell proliferation and death. State of NE-LB595 — $100,000 — [1 July 2009-30 June 2014].


Hanson, N. D. [Investigator]. Development of a molecular diagnostic protocol for the detection of different plasmid-encoded AMPC genes using molecular beacons and multiplex real time PCR technology. BD Diagnostic Systems — $5,325 — [1 September 2008].
Hanson, N. D. [Investigator]. Molecular characterization of AMPC resistance. Baylor College of Medicine — $190 — [10 April 2011-31 December 2011].

Hanson, N. D. [Investigator]. Molecular characterization of AMPC resistance. Orchid Research Laboratories Limited — $4,060 — [10 September 2010-31 December 2011].


Hanson, N. D. [Investigator]. Pilot study to examine chromosomal and transcriptional modifications between two clinical isolates of klebsiella pneumoniae: A KPC and non-KPC producer. Merck & Company, Inc.— $14,015 — [1 September 2010-31 August 2011].

Hanson, N. D. [Investigator]. Potential for collateral damage associated with the exposure of KPC-producing organisms to different antibiotic drug classes. Merck & Company, Inc.— $711 — [1 December 2009-30 December 2013].

Hanson, N. D. [Investigator]. Potential role of extended-spectrum AmpCs in decreased susceptibility to CXA-101 among AMPC-derepressed P. Aeruginosa. Cubist Pharmaceuticals — $7,606 — [30 September 2011-1 June 2013].


Heaney, R. P. [Investigator]. International Dairy Foods Association educational project. International Dairy Foods Association — $9,000 — [1 August 2006].

Heaney, R. P. [Investigator]. Merck educational grant. Merck & Company, Inc.— $250 — [1 October 2006].

Heaney, R. P. [Investigator]. Phone interview/consultation regarding sclerostin antibody product and osteoporosis. Cline Davis & Mann — $300 — [21 February 2011].


Huerter, C. [Investigator]. Phase 3, multicenter, open-label extension study designed to describe the safety, tolerability and efficacy of long-term administration of the human monoclonal antibody against IL-12 in subjects with moderate to severe chronic plaque psoriasis. Abbott Laboratories — $5,956 — [1 April 2008].

Huerter, C. [Investigator]. Randomized, double-blind,placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing psoriasis area and severity index (PASI) response in
patients with moderate to severe chronic plaque-type psoriasis. Novartis Pharmaceuticals Corporation — $40,809 — [31 August 2009].

Huggett, K. N. [Investigator]. Randomized trial to improve tobacco cessation skills among medical students. National Institutes of Health — $22,940 — [6 July 2009-31 May 2014].

Hunter, C. B. [Investigator]. Multicenter, randomized, double-blind, parallel group active controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction. Novartis Pharmaceuticals Corporation — $32,295 — [1 April 2010].


Lund, R. J. [Investigator]. Randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, Aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality. Novartis Pharmaceuticals Corporation — $9,476 — [1 July 2008].

Lund, R. J. [Investigator]. 12-week, open-label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer hcl in lowering serum phosphate levels in chronic kidney disease patients on hemodialysis. Novartis Pharmaceuticals Corporation — $5,584 — [16 April 2008].

Lund, R. J. [Investigator]. 28-week extension to a 24-week multicenter, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerability of vildagliptin 50 mg qd versus sitagliptin 25mg qd in patients with type 2 diabetes and severe renalal insufficiency. Novartis Pharmaceuticals Corporation — $6,355 — [1 October 2008].


Lund, R. J. [Investigator]. Impact SHPT study: Study to evaluate the improved management of IPTH with paricalcitol-centered therapy vs cinacalcet therapy with low-dose vitamin-D in hemodialysis patients with secondary hyperparathyroidism. Abbott Laboratories — $5,214 — [20 October 2009].

Lund, R. J. [Investigator]. Multicenter, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50mg qd or 100mg qd) versus sitagliptin (25mg qd) in patients with type 2 diabetes and severe renal insufficiency. Novartis Pharmaceuticals Corporation — $270 — [10 August 2007].

Lund, R. J. [Investigator]. Randomized, double-blind, placebo controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality. Novartis Pharmaceuticals Corporation — $16,113 — [1 July 2008].


Lynch, H. T. [Investigator]. Multiple myeloma collaboration subcontract with Memorial Sloan Kettering Cancer Center. Lymphoma Foundation — $15,000 — [1 July 2011-30 June 2013].


Mackin, R. B. [Investigator]. Evaluation of rabbit anti-PC1 antibody for western blots. Millipore Corporation — $1,600 — [1 June 2006].


Mohiuddin, S. M. [Investigator]. HFF program: Chair start-up award. Health Future Foundation — $238,084 — 1 July 2011-30 June 2012.


Mooss, A. N. [Investigator]. Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2d). Hoffmann-LaRoche, Inc.— $3,500 — 1 August 2010.


Morrow, L. E. [Investigator]. Randomized, double-blind, placebo-controlled, phase 3 study of the efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis. InterMune, Inc.— $9,139 — 1 July 2011.


Murray, T. [Investigator]. Cancer and smoking disease research program: Administration and planning program. State of NE-LB595 — $140,000 — 1 July 2009-30 June 2014.


Nichols, D. H. [Investigator]. UNMC CoBRE: Molecular analysis of the LMX1A (Dreher) mutant inner ear. National Institutes of Health — $72,250 — [1 July 2011-30 June 2012].


Ramaswamy, S. [Investigator]. Comparison of bone mineral density changes during treatment with risperidone or aripiprazole in adolescents. Bristol-Myers Squibb — $5,280 — [17 October 2006]


Ramaswamy, S. [Investigator]. Fifteen-month, prospective, randomized, active-controlled, open-label, flexible-dose study of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to treatment failure in adults with schizophrenia who have been recently released from jail. (Janssen Scientific Affairs, L.L.C.— $12,455 — [1 May 2010].


Recker, R. R. [Investigator]. Randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Nordic Bioscience — $77,440 — [1 April 2010].


Rendell, M. S. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with alogliptin in addition to standard of care in subjects with type 2 diabetes and acute coronary syndrome. Takeda Global Research & Development Center, Inc.—$7,624 — [1 February 2010-1 February 2012].

Rendell, M. S. [Investigator]. Randomized, double-blind, placebo and active-controlled, parallel-group, multicenter study to determine the efficacy and safety of albiglutide when used in combination with metformin compared with metformin plus sitagliptin, metformin plus glimepiride, GlaxoSmithKline Company — $973 — [1 January 2009].

Rendell, M. S. [Investigator]. Randomized, double-blind, placebo and active-controlled, parallel-group, multicenter study to determine the efficacy and safety of two dose levels of albiglutide administered in combination with metformin and glimepiride compared with metformin plus glimepiride and pioglitazone in subjects with type 2 diabetes mellitus. GlaxoSmithKline Company — $1,170 — [1 January 2009].

Rendell, M. S. [Investigator]. Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the efficacy and safety of two dose levels of albiglutide compared with placebo in subjects with type 2 diabetes mellitus. GlaxoSmithKline Company — $734 — [1 January 2009].

Rendell, M. S. [Investigator]. Randomized, open-label, active-controlled, parallel-group, multicenter study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro. GlaxoSmithKline Company — $2,913 — [1 January 2009].

Rendell, M. S. [Investigator]. Randomized, open-label, parallel-group, multicenter study to determine the efficacy and long term safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes mellitus. GlaxoSmithKline Company — $19,187 — [1 July 2010].

Rendell, M. S. [Investigator]. Apidra (insulin glulisine) administered in a fixed bolus regimen vs variable bolus regimen in adult subjects with type 2 diabetes receiving lantus (insulin glargine) as basal insulin: A multicenter randomized parallel open-label clinical study. Aventis Pasteur, Inc.—$1,398 — [1 March 2004].

Rendell, M. S. [Investigator]. Defend-1 long term follow up: Durable-response therapy evaluation for early or new onset type 1 diabetes extension study. Tolerx, Inc.—$4,525 — [1 November 2010].


Rendell, M. S. [Investigator]. Extension trial comparing safety and efficacy of NN5401 plus meal-time insulin aspart for the remaining meals with insulin detemir plus meal-time insulin aspart in type 1 diabetes. Novo Nordisk Pharmaceuticals Inc.—$9,362 — [1 February 2010].


Rendell, M. S. [Investigator]. Multicenter, multinational extension of study CP-MGA031-01 to evaluate the long-term efficacy and safety of teplizumab (MGA031), a humanized, FCR non-binding, anti-CD3

Rendell, M. S. [Investigator]. Multicenter, randomized, double-blind active-controlled clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 Mg Qd or 100 Mg Qd) Versus Sitagliptin (25 Mg Qd) in patients with type 2 diabetes and severe renal insufficiency. Novartis Pharmaceuticals Corporation — $2,047 — [1 October 2007].

Rendell, M. S. [Investigator]. Multicenter, randomized, double-blind, placebo and active controlled study comparing the analgesic efficacy and safety of ABT-639 to placebo in subjects with diabetic neuropathic pain. Abbott Laboratories — $102,356 — [1 May 2011].

Rendell, M. S. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with alogliptin in addition to standard of care in subjects with type 2 diabetes and acute coronary syndrome. Takeda Global Research & Development Center, Inc. — $22,698 — [1 February 2010-1 February 2012].

Rendell, M. S. [Investigator]. Multi-dose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide. GlaxoSmithKline Company — $3,500 — [1 September 2011].

Rendell, M. S. [Investigator]. Phase 1 randomized, blinded, placebo controlled, safety and pharmacodynamic study of BHT3021 with open label cross-over in subjects with type 1 diabetes mellitus. Bayhill Therapeutics — $21,728 — [1 March 2008].


Rendell, M. S. [Investigator]. Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of LX4211 in combination with metformin in subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin treatment. Lexicon Pharmaceuticals, Inc — $30,299 — [1 June 2011].

Rendell, M. S. [Investigator]. Phase 2/3 randomized double-blind multicenter multinational 4-arm controlled dose-ranging study to evaluate efficacy and safety of MGA031 humanized FCR non-binding anti-CD3 monoclonal antibody in children and adults with recent-onset type 1 diabetes. MacroGenics, Inc. — $32,700 — [1 October 2006].

Rendell, M. S. [Investigator]. Phase IIb randomized, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10mg and 25mg) administered orally, once daily over 78 weeks in type 2 diabetic patients receiving once-daily treatment with basal insulin. Boehringer Ingelheim Pharmaceuticals, Inc.— $38,684 — [1 November 2009].

Rendell, M. S. [Investigator]. Phase III randomized, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment. Boehringer Ingelheim Pharmaceuticals, Inc. — $11,542 — [1 May 2011].

Rendell, M. S. [Investigator]. Phase III randomized, double-blind, placebo-controlled, parallel group efficacy and safety study of linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patients in combination with basal insulin therapy. Boehringer Ingelheim Pharmaceuticals, Inc. — $9,126 — [1 November 2009].
Rendell, M. S. [Investigator]. Phase III, multicenter, international, randomized, parallel group, double-blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk. Boehringer Ingelheim Pharmaceuticals, Inc. — $27,695 — [1 March 2011].

Rendell, M. S. [Investigator]. Phase III, multicenter, open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of technosphere insulin inhalation powder, using the Gen2 inhaler, in combination with insulin aspart in combination with insulin glargine. Mannkind Corporation — $16,587 — [1 November 2010].


Rendell, M. S. [Investigator]. Randomized double-blind, placebo-controlled clinical trial to assess the effects of taspoglutide on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease. Hoffmann-LaRoche, Inc.— $7,474 — [1 April 2010].

Rendell, M. S. [Investigator]. Randomized, double-blind, active controlled, parallel-group, multicenter study to determine the efficacy and safety of albiglutide as compared with sitagliptin in subjects with type 2 diabetes mellitus with renal impairment. GlaxoSmithKline Company — $97,850 — [1 July 2010].

Rendell, M. S. [Investigator]. Randomized, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0mg, administered orally once daily) compared to glimepride (1 to 4mg once daily) over two years, in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy. Boehringer Ingelheim Pharmaceuticals, Inc. — $29,620 — [1 February 2008].

Rendell, M. S. [Investigator]. Randomized, double-blind, placebo-and active-controlled, parallel-group, multicenter study to determine the efficacy and safety of albiglutide when used in combination with metformin compared with metformin plus sitagliptin, metformin plus glimepiride. GlaxoSmithKline Company — $13,478 — [1 January 2009].

Rendell, M. S. [Investigator]. Randomized, double-blind, placebo-and active-controlled, parallel-group, multicenter study to determine the efficacy and safety of two dose levels of albiglutide administered in combination with metformin and glimepiride compared with metformin plus glimepiride. GlaxoSmithKline Company — $8,327 — [1 January 2009].

Rendell, M. S. [Investigator]. Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the efficacy and safety of two dose levels of albiglutide compared with placebo in subjects with type 2 diabetes mellitus. GlaxoSmithKline Company — $4,454 — [1 January 2009].


Rendell, M. S. [Investigator]. Randomized, double-masked, placebo-controlled, multicenter, phase 2 study to evaluate the safety and renal efficacy of LY2382770 in patients with diabetic kidney disease due to type 1 or type 2 diabetes. Eli Lilly and Company — $42,869 — [1 September 2010].

Rendell, M. S. [Investigator]. Randomized, open-label, active-controlled, parallel-group, multicenter study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro. GlaxoSmithKline Company — $19,119 — [1 November 2009].
Rendell, M. S. [Investigator]. Randomized, open-label, parallel-group, multicenter study to determine the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes mellitus. GlaxoSmithKline Company — $97,176 — [1 July 2010].

Rendell, M. S. [Investigator]. Randomized, open-label, parallel-group, multicenter study to determine the efficacy and long term safety of albiglutide compared with insulin in subjects with type 2 diabetes mellitus. GlaxoSmithKline Company — $2,234 — [1 January 2009].


Schima, S. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled phase IV trial to to evaluate the effect of saxagliptin on the incidence of cardiovascular death myocardial infarction or ischaemic stroke in patients with type 2 diabetes (SAVOR). AstraZeneca — $9,000 — [1 September 2010].

Schima, S. [Investigator]. Multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with alogliptin in addition to standard of care in subjects with type 2 diabetes and acute coronary syndrome. Takeda Global Research & Development Center, Inc. — $11,630 — [1 February 2010].


Schuller, D. [Investigator]. Long-term extension, multicenter, multinational study to evaluate the safety and tolerability of oral bay 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic pulmonary arterial hypertension (PAH). Patent-2 Study. Bayer Corporation — $8,250 — [1 March 2011].


Schuller, D. [Investigator]. Phase 2, Open-label dose-escalation study in subjects with pulmonary arterial hypertension, (PAH, WHO Group 1) and pulmonary hypertension secondary to idiopathic pulmonary fibrosis, (PH-IPF WHO Group 3) using inhaled nitrosyl. GeNO, LLC — $6,750 — [1 March 2011].


Schuller, D. [Investigator]. Pulmonary arterial hypertension (PAH-EX) quality enhancement research initiative extension program. Actelion Pharmaceuticals, Inc. — $6,500 — [18 February 2011].

Schuller, D. [Investigator]. Randomized, double-blind, placebo-controlled multicenter, multi-national study to evaluate the efficacy and safety of oral bay 63-2521 (1 mg, 1.5 mg, or 2.5 mg TiD) in patients with symptomatic pulmonary arterial hypertension (PAH). Bayer Corporation — $28,659 — [3 January 2011].

Schuller, D. [Investigator]. Randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Novartis Pharmaceuticals Corporation — $8,123 — [1 June 2010].


Silberstein, P. [Investigator]. Multicenter treatment protocol for expanded access use of ipilimumab (BMS-734016) monotherapy in subjects with unresectable stage III or stage IV melanoma. Bristol-Myers Squibb — $7,100 — [1 August 2010].

Silberstein, P. [Investigator]. Observational study of avastin (bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic non-small cell lung (excluding predominant squamous cell histology) or locally recurrent or metastatic breast cancer. Genentech, Inc.— $2,200 — [9 February 2007].


Silberstein, P. T. [Investigator]. Multicenter treatment protocol for expanded access use of ipilimumab (BMS-734016) monotherapy in subjects with unresectable stage III or stage IV melanoma. Bristol-Myers Squibb — $1,500 — [1 August 2010].


Swanson, P. [Investigator]. Role of HERC2 in lymphocyte development and V(D)J recombination. State of NE-LB692 — $60,000 — [1 July 2011-30 June 2013].

Tang, J. [Investigator]. Creation of a pendrin with both motor and transport functions. Deafness Research Foundation — $25,000 — [1 July 2011-30 June 2012].


Thomson, K. S. [Investigator]. Comparative activity of carapenems against gram negative bacteria isolated in U.S. Trius Therapeutics — $7,500 — [1 March 2010].


Thomson, K. S. [Investigator]. KPC PCR and phenotypic testing of 5 strains of enterobacteriaceae. University of Kentucky Hospital — $5,050 — [1 January 2009].


Thomson, K. S. [Investigator]. Reference strains of gram-negative bacteria with characterized resistance mechanisms. Novartis Vaccines and Diagnostics, Inc. — $37,000 — [1 September 2011].

Townley, R. G. [Investigator]. Effect of omalizumab on release of histamine and heparin from basophils in subjects with moderate to severe asthma. Streck Laboratories, Inc. — $12,000 — [1 November 2010].

Townley, R. G. [Investigator]. Montelukast can inhibit allergen induced cysLT and IL-13 release from subjects with allergic rhinitis or allergic asthma. Merck & Company, Inc.— $4,000 — [1 May 2007-30 April 2008].

Townley, R. G. [Investigator]. Phase II, randomized, double-blind, placebo controlled, dose-ranging study to evaluate lebrikizumab (MILR1444A) in adult patients with asthma who are not taking inhaled corticosteroids (Molly). Genentech, Inc. — $8,851 — [1 February 2010].

Townley, R. G. [Investigator]. Phase II, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of lebrikizumab (MILR1444a) in adult patients with asthma who are inadequately controlled on inhaled corticosteroids (Milly). Genentech, Inc. — $4,850 — [1 July 2009].

Townley, R. G. [Investigator]. Randomized, double-blind, placebo-controlled, parallel group, multicenter, two-year study to evaluate the ocular safety of once-daily, fluticasone furoate nasal spray 110 mcg in adults and adolescents 12 years of age and older with perennial allergic rhinitis. GlaxoSmithKline Company — $18,162 — [1 October 2008].


Tu, Y. [Investigator]. Salmeterol and fluticasone regulate RGS2 to modulate airway hypertresponsiveness in asthma. GlaxoSmithKline Company — $76,206 — [1 May 2011-31 July 2013].

Varman, M. [Investigator]. Phase III clinical trial to study the immunogenicity, tolerability, and manufacturing consistency of V503 (a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine) in preadolescents and adolescents (9 to 15 year olds) with a comparison to young women (16-26 year olds). Merck & Company, Inc. — $5,592 — [6 July 2009-30 June 2011].


Varman, M. [Investigator]. Phase 1/2a, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-559, a live attenuated intranasal vaccine against respiratory syncytial virus in health 1 to <12 month-old. MedImmune, Inc. — $8,375 — [2 July 2009].
Varman, M. [Investigator]. Randomized, double-blind, double-dummy, comparative, multicenter study to assess the safety and efficacy of topical retapamulin ointment, 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant staphylococcus aureus. GlaxoSmithKline Company — $500 — [1 February 2010].


White, M. [Investigator]. Randomized, double-blind, palcebo-controlled, parallel group, multinational trial to assess the prevention of thrombotic events with ticagrelor compared to placebo on a background of acetyl salicylic acid (ASA) therapy in patients with history of myocardi. AstraZeneca — $8,000 — [14 April 2011].


Williams, M. A. [Investigator]. Mitochondrial dysfunction, oxidative damage and inflammation in claudication. National Institutes of Health — $4,549 — [1 July 2010-30 June 2014].

Williams, M. A. [Investigator]. Mitochondrial dysfunction, oxidative damage and inflammation in claudication. National Institutes of Health — $60,473 — [1 October 2011-30 September 2012].

Wilson, D. R. [Investigator]. Long-term safety, tolerability and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder: a randomized, active comparator-controlled trial. Dainippon Sumitomo Pharma America — $2,044 — [22 May 2008].

Yilmazer-Hanke, D. [Investigator]. Role of emotional changes in limbic areas and in epilepsy. State of NE-LB692 — $100,000 — [1 July 2011-30 June 2014].


Zetterman, R. [Investigator]. Investment in basic science research infrastructure. Health Future Foundation — $399,004 — [1 July 2011-30 June 2012].

School of Nursing


Norris, J. [Investigator]. Advanced education nurse traineeship. Health and Human Services, Division of Nursing — $22,491 — [1 July 2011-30 June 2012].

Norris, J. [Investigator]. Advanced education nursing traineeship. Health and Human Services, Division of Nursing — $25,481 — [1 July 2010-30 June 2011].


Rubarth, L. [Investigator], Sandhurst, H., Schoening, A., Cosimano, A. HFF Faculty Development: Use of online support and NICU education to decrease stress for prenatal patient on bedrest: A pilot study. Health Futures Foundation Faculty Development Grant —$18,033 — [1 July 2010-30 June 2012].


**School of Pharmacy and Health Professions**


Doll, J. [Investigator]. Omaha Nation suicide prevention plan-project hope. Health and Human Services — $9,566 — [1 October 2010-30 September 2011].


Galt, K. A. [Investigator]. Creighton research infrastructure program to achieve sustainability project—primary project. Health and Human Services — $160,469 — [30 September 2009-31 July 2013].
Galt, K. A. [Investigator]. Oral health access for young children program. Health and Human Services — $51,000 — [1 January 2010-31 August 2012].


Grindstaff, T. [Investigator]. Effects of talocrural joint mobilization on lower extremity h-reflex in individuals with chronic ankle instability. Nebraska Foundation for Physical Therapy — $3,000 — [15 August 2011-30 November 2012].

Henriksen, B. [Investigator]. Synthesis of peptidomimetic analogs of the C-terminal region of substance P. ICW Technologies — $50,900 — [1 August 2011-31 August 2013].


Malesker, M. A. [Investigator]. Observational prospective registry to identify demographic and clinical characteristics of patients hospitalized with euvolemic and hypervolemic hyponatremia and assess the comparative effectiveness of available treatments and the impact on resource. Otsuka America Pharmaceutical, Inc. — $2,450 — [29 January 2011].


Vice President for Academic Affairs


Walker, R. [Investigator]. NSG-Nebraska state grant. State of NE-Education — $162,634 — [1 July 2010-30 June 2011].


Vice President for Health Sciences


Salzinger, F. [Investigator]. Installment of a dedicated sanitary sewer main from the autoclave in the animal resource facility out to the street. Health Future Foundation — $72,606 — [31 January 2011-30 June 2011].


Hanna, F. F. (2011). *Processus de Facundia*


Theses and Dissertations

May 2011

Borchers, Ryan. The revengers: A novel. Master of Arts (English) – Dr. David Mullins (Major Advisor).

Brown, Silas. An examination of national factors that influence levels of perceived intellectual property protection. Master of Arts (International Relations) – Dr. Kristie Briggs (Major Advisor).

Cartaya, Erin. Like, share or continue shopping: Branding identity and consumerizing online literacy. Master of Arts (English) – Dr. Robert Dornsife (Major Advisor).

Gibilisco, Michael. Characteristics of fuzzy social choice. Master of Arts (International Relations) – Dr. Terry Clark (Major Advisor).

Johnson, Matthew. Committing the military today: Is the Powell or Mullen doctrine most relevant? Master of Arts (International Relations) – Dr. Terry Clark (Major Advisor).


Kokubun, Kelsey. Differentiation of porcine mesenchymal stem cells as a potential therapeutic application for epithelial regeneration. Master of Science (Biomedical Sciences) – Dr. Devendra Agrawal (Major Advisor).

Montag, Kassandra. Asylum. Master of Arts (English) – Dr. Susan Aizenberg (Major Advisor).


Schutt, Charles. Prion strain conformational stability and the role of PrPc in prion strain interference. Master of Science (Medical Microbiology and Immunology) – Dr. Jason Bartz (Major Advisor).

Segrist, Samuel. Higher than God. Master of Arts (English) – Dr. Mary Helen Stefaniak (Major Advisor).

Simmons, Kelly. Political instability: Governance, perceptions of well-being and mobilization. Master of Arts (International Relations) – Dr. James Wunsch (Major Advisor).


Woldemariam, Semere. Digital holographic micro-interferometry for the measurement of the refractive index of biological cells. Master of Science (Physics) – Dr. Michael Nichols (Major Advisor).

Zabrowski, Mary. The rhetoric of taste education: Food’s rhetorical influence in the creation of gastronome principles and identity. Master of Arts (English) – Dr. Gina Merys (Major Advisor).

August 2011

Borda, Matthew. Spoiling to survive: Why terrorism escalates after a government concession. Master of Arts (International Relations) – Dr. Terry Clark (Major Advisor).

Dossou, Starlette. Tubulin isotypic diversity in mammalian cilia. Doctor of Philosophy (Biomedical Sciences) – Dr. Richard Hallworth (Major Advisor).
Gadgil, Prajakta. A comparative study between high potency dry powder inhalation and nebulized solution of vancomycin hydrochloride for lung delivery. Master of Science (Pharmaceutical Sciences) – Dr. Justin Tolman (Major Advisor).

Kennedy, Jennifer. Our children’s lunch: Putting a small meal in the big picture of food and people. Master of Arts (Liberal Studies) – Dr. Richard White (Major Advisor).

Mistry, Pinal. Surface modified solid lipid curcumin nanoparticles for oral delivery. Master of Science (Pharmaceutical Sciences) – Dr. Alekha Dash (Major Advisor).


Ross, Brian. Life’s Circles. Master of Arts (English) – Dr. Gina Merys (Major Advisor).

Sai, Adarsh. Role of vitamin D receptor and vitamin D binding protein restriction fragment length polymorphisms in determining dose response to vitamin D: A randomized double blind placebo controlled trial. Master of Science (Clinical and Translational Science) – Dr. Devendra Agrawal (Major Advisor).

Torpin, Trevor. Constraints on universal extra-dimensional dark matter from direct detection results. Master of Science (Physics) – Dr. Gintaras Duda (Major Advisor).

December 2011

Armas, Laura. Histomorphometric analysis of bone in healthy, young patients with Type 1 diabetes mellitus. Master of Science (Clinical and Translational Science) – Dr. Devendra Agrawal (Major Advisor).

Campbell, Sean. Urban heat island enhancement to deep, moist convection over Omaha, Nebraska in late June and early July of 2008. Master of Science (Atmospheric Sciences) – Dr. Joseph Zehnder (Major Advisor).

Carrico, Cathy. Pertussis cocooning: Assessing the infant’s family pertussis vaccination status. Doctor of Nursing Practice (Nursing) – Dr. Katie O’Keefe (Major Advisor).

Garrett, Katherine. Dark matter annihilation and the observed positron excess. Master of Science (Physics) – Dr. Gintaras Duda (Major Advisor).


Hallman, Timothy. Effect of hair cell microRNAs on gene expression profiles of cultured mouse otic precursor cells. Master of Science (Biomedical Sciences) – Dr. Garrett Soukup (Major Advisor).

Huijgens, Mary. A directed acyclic graph demonstrating the effects of population aging on saving and interest rates in Europe. Master of Arts (International Relations) – Dr. Terry Clark (Major Advisor).


Yager, Amy. Adolescent use of social networking to gain sexual health information. Doctor of Nursing Practice (Nursing) – Dr. Katie O’Keefe (Major Advisor).
Illustrations

All of the images that appear in this document are part of the photographic collection of the various Creighton University Schools and Colleges, and Marketing and Communications.

- Dr. Eric Haas & Student, Chemistry Lab, College of Arts & Sciences Front Cover
- Audry Bradshaw, Nursing Student, School of Nursing Table of Contents
- Dental Student in Lab, School of Dentistry 63
- Dr. Catherine Opere & Student, School of Pharmacy & Health Professions 93
- Creighton Company of Dancers 94
- Dr Nancy Hanson, Medical Microbiology and Immunology, School of Medicine Back Cover

Acknowledgements

The Creighton University Faculty Bibliography is an annual compilation of Creighton’s research and scholarly endeavors and as such could not be produced without the full support of the University’s educators, researchers and staff. We thank those who, each year, provide the research, publication, and grant information that comprises this document. In addition, there individual members of the Creighton community who deserve special thanks for their contributions to this year’s edition:

- Gail Jensen, PhD., Associate Vice President for Research in Academic Affairs and Dean, Graduate School and University College;
- James Bothmer, Richard Jizba, and the staff at the Health Sciences Library;
- Rick Davis, Marketing & Communications;
- Phil Beagle, Office of eLearning and Academic Technologies, School of Pharmacy and Health Professions;
- Kathy Taggart, Associate Vice President for Research and Compliance, and Beth Herr, Director of Sponsored Programs Administration.